Personal care composition and method for suppressing unpleasant odors

Abstract

This disclosure relates to compositions and methods for controlling personal care odors. More specifically, this disclosure relates to compositions comprising a ferment extract of Brevibacillus laterosporus or a fraction thereof for controlling body odor and methods for using the same. Compositions containing a ferment extract of Brevibacillus laterosporus are suitable for use as underarm / axillary deodorants and for odor control in personal care applications.

Description

[Technical Field]

[0001] Cross-reference of related applications This application claims the benefits of U.S. Provisional Patent Application No. 63 / 490,569, filed on 16 March 2023, which is incorporated herein by reference in its entirety.

[0002] This disclosure relates to personal care compositions and methods for suppressing body surface odor. More specifically, this disclosure relates to compositions comprising a fermented extract of Brevibacillus laterosporus or a fraction thereof for preventing and / or reducing body surface odor, and methods for using the same. Compositions containing a fermented extract of Brevibacillus laterosporus are suitable for use as deodorizing compositions and cosmetic compositions for odor suppression.

[0003] Reference to electronically submitted sequence listings The sequence listing (name: 20240213_NB42196PCT_sequencelisting; size: 36,960 bytes; creation date: February 13, 2024), which is submitted electronically with this application as an XML file, constitutes part of this application and is incorporated herein by reference in its entirety. [Background technology]

[0004] Human axillary secretions (sweat) are often odorless. The generation of axillary odor is mainly due to the biotransformation of odorless secretory molecules by microorganisms present in the axillary region. Based on phylogenetic analysis, various microorganisms are present in the axillary region (Troccaz, et al., Microbiome 3, 3, 2015; James, et al., FEMS Microbiol Ecol., 2013, 83(3):527-540; Rudden, et al., Sci Rep. 2020, 10:12500). Staphylococcus species are one of the major microbial groups involved in the production of axillary odor compounds.

[0005] Preventing body odor (such as underarm odor) has long been desired.

[0006] Mechanisms for providing deodorization include applying antimicrobial substances to the axillary skin, providing fragrance compositions that can mask malodors, and capturing malodorous molecules (for example, by applying cyclodextrin to inhibit β-lyase). Ethylenediaminetetraacetic acid (EDTA) and other metal ion sequestering agents can also be used as deodorizing active ingredients that act to remove important metal nutrients that bacteria require for the enzymatic formation of free acids. In the cosmetics field, it is well known that astringent salts such as aluminum salts and / or zirconium salts are used as antiperspirants that have the effect of restricting or further removing sweat flow. In some people, the application of products containing these metal salts has been shown to cause skin irritation. [Overview of the project] [Problems that the invention aims to solve]

[0007] Consumer demand for formulations using renewable resource-derived ingredients has steadily increased in recent years, spurring further research into solutions that replace existing ingredients with sustainable alternatives while offering products with attractive properties and performance.

[0008] There remains a need to explore effective, environmentally friendly, and sustainable solutions for reducing body surface odors that are effective in suppressing malodors, easily formulated, and well-tolerated by users. [Means for solving the problem]

[0009] This disclosure relates to a composition comprising a fermented extract of Brevibacillus laterosporus for personal care odor suppression and a method for using the same. More specifically, this disclosure relates to a composition comprising at least one fermented extract of Brevibacillus laterosporus or a fraction thereof, and a method for providing odor suppression in personal care applications.

[0010] This invention is based on the discovery that a fermented extract from Brevibacillus laterosporus functions as an odor-suppressing component.

[0011] In one embodiment, the inventors unexpectedly observed that an effective amount of Brevibacillus laterosporus ferment extract functions as an odor inhibitor, preventing and / or reducing body odors such as axillary and foot odor.

[0012] In one embodiment, the composition is an odor-suppressing composition comprising an effective amount of Brevibacillus laterosporus ferment extract, the extract preventing and / or reducing body surface odor. In one embodiment, the Brevibacillus laterosporus ferment extract is selected from the group consisting of cell pellet extract obtained from Brevibacillus laterosporus ferment, cell-free supernatant obtained from Brevibacillus laterosporus ferment, whole broth ferment extract obtained from Brevibacillus laterosporus ferment, and any one combination thereof.

[0013] In one embodiment, the composition is an odor-suppressing composition comprising an effective amount of Brevibacillus laterosporus ferment extract, the extract preventing and / or reducing body odor, the body surface being selected from the group consisting of the axillary region of the body, skin, feet, hair and scalp.

[0014] In one embodiment, the composition is an odor-suppressing composition containing an effective amount of Brevibacillus laterosporus ferment extract, the extract preventing and / or reducing body surface odor, and the composition is a personal care or cosmetic composition.

[0015] In one embodiment, the composition is a deodorizing composition for preventing or reducing body odor, comprising an effective amount of Brevibacillus laterosporus ferment extract as a deodorizing active ingredient, wherein the effective amount of extract prevents and / or reduces body odor, and the ingredient is incorporated into a deodorant vehicle.

[0016] In one embodiment, the method is a method for preventing or reducing malodor from a body surface, comprising the step of applying to the body surface an effective amount of Brevibacillus laterosporus ferment extract or a composition comprising an effective amount of Brevibacillus laterosporus ferment extract, wherein the extract prevents and / or reduces the malodor from the body surface.

[0017] In one embodiment, the method is a method for preventing or reducing malodor on the surface of a human or animal, such as the axillary region of the body or the feet, the method comprising applying to the surface an effective amount of an extract of a Brevibacillus laterosporus fermentation product, or a composition comprising an effective amount of an extract of a Brevibacillus laterosporus fermentation product, wherein the extract is a method for preventing and / or reducing the malodor on the surface.

Mode for Carrying Out the Invention

[0018] The features and advantages of the present disclosure will be more readily understood by those skilled in the art upon reading the following detailed description. It should be understood that, for clarity, the specific features of the present disclosure described above and below in connection with separate embodiments may be provided either singly or in combination. Conversely, for brevity, the various features of the present disclosure described in connection with a single embodiment may be provided separately or in any sub-combination. It will be understood that the embodiments described below in connection with one broad aspect of the invention are equally applicable to each of the other broad aspects of the invention described above. It will be further understood that the embodiments described below may be combined unless the context indicates otherwise.

[0019] Microorganisms, Fermentation Products, and Fermentation Product Extracts As used herein, "microorganism" or "microbe" refers to bacteria, fungi, viruses, protozoa, archaea and other microorganisms or microscopic organisms.

[0020] In some embodiments, the microorganisms suitable for use in the present invention can be subjected to treatments for disabling their replication ability, such as heat exposure, drying, gamma irradiation, or ultraviolet irradiation. Non-replicating microorganisms suitable for use in the present invention can be dead cells or living cells that have become unable to divide. Non-replicating microorganisms suitable for use in the present invention can be intact cells or cells that have been subjected to partial or complete cell lysis. In some embodiments, the non-replicating cells can include a mixture of intact cells and cell lysates.

[0021] The microorganisms suitable for use in the present invention can be included in the compositions according to the present invention in a living form, a semi-active or inactivated form, or a dead form. The "inactivated" or "dead" microorganisms in the context of the present invention are microorganisms that can no longer form colonies in culture. Dead or inactivated microorganisms can have an intact or disrupted cell membrane. Dead or inactivated microorganisms can be obtained by any method known to those skilled in the art.

[0022] Examples of microorganisms suitable for use in the present invention include Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited with the Westerdijk Fungal Biodiversity Institute (WFDB) under accession number CBS149108. The phylogenetic identity of Brevibacillus laterosporus was determined by sequencing the 16S region using primer set A (5'-GTGCCAGCMGCCGCGGTAA-3, SEQ ID NO: 2) and primer set B (5'-CGGTTACCTTGTTACGACTT, SEQ ID NO: 3).

[0023] The 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G2 is as follows: [ka]

[0024] Suitable microorganisms for use in this invention include, but are not limited to, *Brevibacillus laterosporus* having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of *Brevibacillus laterosporus* strain G2 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; and *Brevibacillus laterosporus* strain A8.11 (Brevibacillus laterosporus) deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109. Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (Sequence ID 1) of Brevibacillus laterosporus (derived from G2); Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (Sequence ID 1) of Brevibacillus laterosporus ALS311 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; Westerdijk Fungal Biodiversity Institute At least 97% of the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited with the World Food Database (WFDB) under the number CBS149786 were compared.Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing 0% sequence similarity; Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787 One example is *Brevibacillus laterosporus*, which possesses a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence of *G11_1_1* (Sequence ID 1).

[0025] In one aspect of the present invention, a fermented product is provided.

[0026] As used herein, the term “fermentation product” should be understood as a composition (compound mixture) produced by growing a living microorganism (microbial strain) in a nutrient medium. The fermentation product may include cell population components derived from the microorganism, unused medium components, and metabolites (i.e., unused substrate and / or fermentation end products). As used herein, “cell population components” refers to any mixture of proteins, lipids (i.e., membranes), carbohydrates, extracellular polysaccharides, metabolites, etc., from the grown microorganism. For example, when a microorganism grows, new cells are produced that generally include additional cell populations such as, but are not limited to, cell membranes, nucleic acids (i.e., DNA and / or RNA), intracellular structures, polysaccharides, and proteins (i.e., membrane-bound, secretory, and / or intracellular).

[0027] Examples of fermented products used in the present invention include those derived from the microorganism Brevibacillus laterosporus.

[0028] The growth medium used to prepare the fermented product is any medium containing the necessary nutrients suitable for the growth of microorganisms suitable for use in the present invention. Suitable nutrients include, but are not limited to, amino peptides, peptides, yeast extracts, salts, sugars, hydrocarbons, and / or vitamins. The medium may be based on dairy products such as milk, grains, fruits, and / or vegetables.

[0029] In one embodiment, the fermented product used in the present invention comprises a fermented product from the microorganism Brevibacillus laterosporus, wherein the Brevibacillus laterosporus has a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of non-spore-forming Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2), deposited at the WFDB (Westerdijk Fungal Biodiversity Institute) under number CBS149109; and Brevibacillus laterosporus ALS311, deposited at the WFDB (Westerdijk Fungal Biodiversity Institute) under number CBS149785, with respect to at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1).Brevibacillus laterosporus having a 16S ribosomal RNA sequence with 0% sequence similarity; Brevibacillus laterosporus having a 16S ribosomal RNA sequence with at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; Brevibacillus laterosporus having a 16S ribosomal RNA sequence with at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788 The group is comprised of *Brevibacillus laterosporus* having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (Sequence ID 1) of *Brevibacillus laterosporus* ALS321, and *Brevibacillus laterosporus* having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (Sequence ID 1) of *Brevibacillus laterosporus* G11_1_1 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787.

[0030] To obtain an effective amount of active substance in the ferment, the ferment can be further concentrated before being included in the composition. The ferment extract can be produced from the ferment described herein, and the ferment can be spray-dried or freeze-dried before being included in the composition.

[0031] It will be apparent that the fermented product can be used directly in the compositions and methods of the present invention, or that one or more fractions or extracts containing the active substance can be isolated from the fermented product by any suitable means before use.

[0032] In one aspect of the present invention, a fermented extract is provided. Examples of fermented extracts for use in the present invention include fermented products derived from the microorganism Brevibacillus laterosporus.

[0033] As used herein, the term “fermentation extract” refers to an extract or fraction from a fermentation produced by growing a living microorganism (microbial strain) in a nutrient medium as described above. In one embodiment, the fermentation extract is an extract of a fermentation produced by growing the species Brevibacillus laterosporus.

[0034] In one embodiment, the fermentation extract is the cell-free supernatant of the fermentation. As used herein, “cell-free supernatant,” “fermentation supernatant,” “cell-free fermentation,” or “fermentation filtrate” are used interchangeably and refer to a fermentation extract substantially free of viable cells, e.g., the supernatant of a cell culture of at least one microorganism from which cells have been removed. Cells can be removed from a cell culture by any method known in the art, and it is understood that such cell removal (e.g., by centrifugation, filtration) may still result in a cell-free supernatant that may contain trace amounts of cells or cell debris. Methods for separating cells from growth media are well known in the art and can utilize physical methods, e.g., centrifugation, filtration, ultrafiltration, tangential flow filtration, volumetric filtration, or reverse osmosis to produce cell pellets and culture supernatants. Alternatively or in addition, the separation method may be ligand-based, comprising an antibody that specifically binds to, for example, Brevibacillus laterosporus. The antibody can be conjugated to a solid support such as magnetic beads. In one embodiment, the cell-free supernatant is obtained by filtering or centrifugation of the culture medium in which Brevibacillus laterosporus cells were cultured.

[0035] In one embodiment, the cell-free supernatant is obtained by filtration or centrifugation of the Brevibacillus laterosporus ferment.

[0036] In one embodiment, cells were pelletized (centrifuged at 4,000-8,000 × g), and the supernatant was passed through a 0.2 μm filter to remove cells from the Brevibacillus laterosporus fermentation, thereby obtaining an essentially cell-free supernatant.

[0037] In one embodiment, the fermentation extract for use in the present invention is a Brevibacillus laterosporus fermentation extract essentially derived from a cell-free fermentation. The term “essentially derived from” in relation to the fermentation means that at least 90% of the fermentation has a specified characteristic (e.g., being a cell-free fermentation). Preferably, at least 95% has the specified characteristic. Preferably, at least 97% has the specified characteristic. Preferably, at least 99% has the specified characteristic. In some embodiments, at least 100% has the specified characteristic.

[0038] The compositions and methods and / or fermentation extracts for use of the present invention may not substantially contain viable cells of Brevibacillus laterosporus, and typically the viable cells are 0 (or substantially 0) cells / mL of the fermentation.

[0039] In another embodiment, the fermentation extract is an extract of a cell pellet obtained from the fermentation by pelletizing the cells. The cell pellet can be obtained by centrifugation of the fermentation and removal of the cell-free supernatant.

[0040] In one embodiment, the cell pellet extract is obtained from the Brevibacillus laterosporus ferment by pelletizing the cells (centrifugation at 4,000-8,000 × g), draining the supernatant, and leaving a portion of the cell pellet. The pellet is resuspended in acidic water (1 / 10 v / v) at pH 2.0-4.0, vortexed, pelletized by centrifugation (4,000-8,000 × g), and the extract is passed through a 0.2 μm filter. Optionally, the cell pellet may be resuspended in alkaline water (1 / 10 v / v) with a pH higher than 8.5. The cell pellet may be suspended in any solution or under any conditions that produce an effective amount of the ferment extract solution.

[0041] Starting with a cell pellet has the advantage of allowing the volume of resuspension (extract volume) to be determined to produce an effective amount of active extract, and / or further concentration to produce an effective amount of active extract. Furthermore, by resuspending the pellet in water or non-fermented broth liquid, inactive components of the fermented broth that may interfere with the active substances in the cell pellet extract are reduced or removed.

[0042] In another embodiment, the Brevibacillus laterosporus ferment extract is produced by combining the cell-free supernatant fraction with the cell pellet extract.

[0043] In yet another embodiment, the Brevibacillus laterosporus ferment is a ferment extract prepared by first adjusting the pH of the ferment (total fermentation broth) to 2.0–4.0, then pelletizing the insoluble cellular material, and optionally filtering the supernatant through a 0.2 μm filter to obtain a cell-free supernatant (also called "total broth ferment extract"). The acid used for pH adjustment can be hydrochloric acid, but any acid capable of adjusting the pH of the fermentation broth to 2.0–4.0 can be used. When preparing the total broth ferment extract of the Brevibacillus laterosporus ferment in this manner, it contains the active substances present in both the cell-free supernatant and the cell pellet extract described herein.

[0044] Alternatively, the Brevibacillus laterosporus ferment is a ferment extract prepared by first adjusting the pH of the ferment (whole ferment broth) to an alkaline pH, then pelletizing the insoluble cellular material, and selectively filtering the supernatant through a 0.2 μM filter to obtain a cell-free supernatant (also called "whole broth ferment extract").

[0045] In one embodiment, the fermentation extract is obtained from a fermentation product produced using a nutrient medium having a pH of 2 to 12.

[0046] In one embodiment, the fermented extract is obtained from a ferment whose pH has been adjusted to 2-12 before obtaining the fermented extract.

[0047] The fermented extract can be further concentrated or purified before being incorporated into the composition to obtain an effective amount of the fermented extract. The fermented extract can also be spray-dried or freeze-dried before being incorporated into the composition.

[0048] It is understood that the production of fermentates and fermentate extracts can vary from batch to batch (between ferments), resulting in different effects of the fermentate extracts. Therefore, it is possible to observe the inter-batch variability in the production of effective amounts of Brevibacillus laterosporus fermentate extract.

[0049] In one embodiment, a fermented product of Brevibacillus laterosporus, a fermented extract, or a composition containing a fermented extract is formulated in a dry or liquid formulation.

[0050] In one embodiment, a Brevibacillus laterosporus ferment, ferment extract, or composition comprising a ferment extract is formulated in at least one form selected from the group consisting of loose or compact powder, granules, liquid suspension or solution, spray solution, gel, roll-on, stick, granules, solid soap, and bath bomb, or any combination thereof.

[0051] The granules are not excluded but can be produced by any means known in the art, such as spray-drying the ferment extract on the core or spray-drying the ferment to form the granules themselves. In one embodiment, the granules are easily dispersible layered granules. The layered granules may comprise a water-soluble and rapidly soluble core surrounded by a coating layer containing at least one effective amount of Brevibacillus laterosporus ferment extract dispersed within a protective matrix. The protective matrix may contain at least one polyhydroxy compound and at least one phosphate compound.

[0052] In one embodiment, the Brevibacillus laterosporus ferment extract described herein is present in amounts of about 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 21% by weight, 22% by weight, 23% by weight, and 24% by weight, based on the total weight of the composition. It is provided in the composition in amounts of 25% by weight, 26% by weight, 27% by weight, 28% by weight, 29% by weight, 30% by weight, 31% by weight, 32% by weight, 33% by weight, 34% by weight, 35% by weight, 36% by weight, 37% by weight, 38% by weight, 39% by weight, 40% by weight, 41% by weight, 42% by weight, 43% by weight, 44% by weight, 45% by weight, 46% by weight, 47% by weight, 48% by weight, 49% by weight, 50% by weight, 55% by weight, 60% by weight, 65% by weight, 70% by weight, 75% by weight, 80% by weight, 85% by weight, 90% by weight, 95% by weight, or up to 100% by weight.

[0053] In one embodiment, the Brevibacillus laterosporus ferment extract described herein is used in amounts of about 0.1% by volume, 0.2% by volume, 0.3% by volume, 0.4% by volume, 0.5% by volume, 0.6% by volume, 0.7% by volume, 0.8% by volume, 0.9% by volume, 1% by volume, 2% by volume, 3% by volume, 4% by volume, 5% by volume, 6% by volume, 7% by volume, 8% by volume, 9% by volume, 10% by volume, 11% by volume, 12% by volume, 13% by volume, 14% by volume, 15% by volume, 16% by volume, 17% by volume, 18% by volume, 19% by volume, 20% by volume, 21% by volume, 22% by volume, 23% by volume, and 24% by volume, based on the total volume of the composition. It is provided in the composition in amounts of 25 vol%, 26 vol%, 27 vol%, 28 vol%, 29 vol%, 30 vol%, 31 vol%, 32 vol%, 33 vol%, 34 vol%, 35 vol%, 36 vol%, 37 vol%, 38 vol%, 39 vol%, 40 vol%, 41 vol%, 42 vol%, 43 vol%, 44 vol%, 45 vol%, 46 vol%, 47 vol%, 48 vol%, 49 vol%, 50 vol%, 55 vol%, 60 vol%, 65 vol%, 70 vol%, 75 vol%, 80 vol%, 85 vol%, 90 vol%, 95 vol% or up to 100 vol%.

[0054] In one embodiment, the fermented extract or fraction thereof for use in the present invention is a Brevibacillus laterosporus strain having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; and Brevibacillus laterosporus strain A8.11 (Brevibacillus laterosporus) deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109. Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (Sequence ID 1) of Brevibacillus laterosporus (derived from G2); Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (Sequence ID 1) of Brevibacillus laterosporus ALS311 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; Westerdijk Fungal Biodiversity Institute At least 97% of the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited with the World Food Database (WFDB) under the number CBS149786 were compared.Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing 0% sequence similarity; Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787 This product contains a fermented extract or fraction thereof from the microorganism *Brevibacillus laterosporus*, selected from the group consisting of *Brevibacillus laterosporus* species having a 16S ribosomal RNA sequence exhibiting at least 97.0% sequence similarity to the 16S ribosomal RNA sequence of *Brevibacillus laterosporus* G11_1_1 (Sequence ID 1).

[0055] Personal care composition containing a fermented extract of Brevibacillus laterosporus for odor suppression. This disclosure includes a Brevibacillus laterosporus ferment extract for odor suppression and a composition comprising an effective amount of the Brevibacillus laterosporus ferment extract.

[0056] In one embodiment, the inventors unexpectedly observed that an effective amount of Brevibacillus laterosporus ferment extract functioned as an odor inhibitor, suppressing body odor.

[0057] "Brevibacillus odor inhibitor," "odor inhibitor," or "odor reducing agent" is understood herein to be an effective amount of Brevibacillus ferment extract designed to prevent and / or reduce odors and not to function merely by covering up or masking the odor. A genuine odor inhibitor provides a sensory and analytically measurable reduction of odor.

[0058] As used herein, the term “malodorous odor” refers to any undesirable or unintended odor on a body surface (including, but not limited to, the axillary body surface, skin, feet, hair, and scalp), as well as compounds that are generally unpleasant or offensive to most people. Examples of malodorous odors include volatile compounds that have a perceived unpleasant odor and may be produced by microorganisms. Microorganisms may be Gram-positive or Gram-negative bacteria (aerobic or anaerobic); algae, protozoa, and / or yeasts or filamentous fungi.

[0059] In some embodiments, the malodorous odor is caused by the genera Acinetobacter sp., Aeromicrobium sp., Brevundimonas sp., Microbacterium sp., Micrococcus luteus, Pseudomonas sp. (e.g., Pseudomonas fluorescens), Staphylococcus sp. (e.g., Staphylococcus epidermidis), Stenotrophomonas sp., Streptomyces sp., Listeria sp., and Streptococcus. This may be related to one or more microorganisms, including one or more bacterial species of the genus Escherichia sp. (and Escherichia sp.). Another example of a foul odor is an unpleasant smell that may be sweat, or body odor associated with an item that has come into contact with a human or animal.

[0060] In one embodiment, the composition is an odor-suppressing composition comprising an effective amount of Brevibacillus laterosporus ferment extract, the extract preventing and / or reducing body surface odor. In one embodiment, the Brevibacillus laterosporus ferment extract is selected from the group consisting of cell pellet extract obtained from Brevibacillus laterosporus ferment, cell-free supernatant obtained from Brevibacillus laterosporus ferment, whole broth ferment extract obtained from Brevibacillus laterosporus ferment, and any one combination thereof.

[0061] In one embodiment, the composition is an odor-suppressing composition comprising an effective amount of Brevibacillus laterosporus ferment extract, the extract preventing and / or reducing body surface odor, the body surface being selected from the group consisting of the axillary body surface (the axillary region of the body or the skin surface under the armpits), skin, feet, hair, and scalp.

[0062] The body surface may be the body surface of a human or an animal.

[0063] In one embodiment, the composition is an odor-suppressing composition containing an effective amount of Brevibacillus laterosporus ferment extract, the extract preventing and / or reducing body surface odor, and the composition is a personal care or cosmetic composition.

[0064] In one embodiment, an odor-suppressing composition containing an effective amount of Brevibacillus laterosporus ferment extract for preventing and / or reducing axillary malodor is a deodorizing composition.

[0065] In one embodiment, a deodorizing composition comprising an effective amount of Brevibacillus laterosporus ferment extract for preventing and / or reducing body odor may be selected from the group consisting of deodorizing sticks, deodorizing sprays, deodorizing powders, and roll-on deodorizers. In one embodiment, the deodorizing stick composition is a wax stick or an alcohol stick. In one embodiment, the deodorizing spray composition is an aerosol spray or a powder aerosol spray.

[0066] In one embodiment, the composition is a deodorizing composition for preventing or reducing body odor, comprising an effective amount of Brevibacillus laterosporus ferment extract as a deodorizing active ingredient, wherein the effective amount of extract prevents and / or reduces body odor, and the ingredient is incorporated into a deodorant vehicle.

[0067] The malodorous compositions or formulations described herein may be in the form of sprays, liquids, gels, powders, roll-ons, sticks, granules, solid soaps, and bath bombs.

[0068] In one embodiment, the composition is a deodorizing composition comprising: i) an effective amount of Brevibacillus laterosporus ferment extract as a deodorizing active ingredient; ii) a liquid carrier deodorizing activator; and optionally iii) a fragrance.

[0069] Odor suppression can be determined, but is not limited to, by evaluation of odor compounds or by any means known in the art, such as evaluation from a sensory panel.

[0070] In one embodiment, the odor-suppressing composition is provided in an amount of approximately 0.1% by volume, 0.2% by volume, 0.3% by volume, 0.4% by volume, 0.5% by volume, 0.6% by volume, 0.7% by volume, 0.8% by volume, 0.9% by volume, 1% by volume, 2% by volume, 3% by volume, 4% by volume, 5% by volume, 6% by volume, 7% by volume, 8% by volume, 9% by volume, 10% by volume, 11% by volume, 12% by volume, 13% by volume, 14% by volume, 15% by volume, 16% by volume, 17% by volume, 18% by volume, 19% by volume, 20% by volume, 21% by volume, 22% by volume, 23% by volume, 24% by volume, 25% by volume, and 26% by volume, relative to the total volume of the composition. The composition contains an effective amount of Brevibacillus laterosporus ferment extract in 27% by volume, 28% by volume, 29% by volume, 30% by volume, 31% by volume, 32% by volume, 33% by volume, 34% by volume, 35% by volume, 36% by volume, 37% by volume, 38% by volume, 39% by volume, 40% by volume, 41% by volume, 42% by volume, 43% by volume, 44% by volume, 45% by volume, 46% by volume, 47% by volume, 48% by volume, 49% by volume, 50% by volume, 55% by volume, 60% by volume, 65% by volume, 70% by volume, 75% by volume, 80% by volume, 85% by volume, 90% by volume, 95% by volume, or up to 100% by volume.

[0071] In one embodiment, the odor-suppressing composition is present in amounts of approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11.0% by weight, 12.0% by weight, 13.0% by weight, 14.0% by weight, 15.0% by weight, 16.0% by weight, 17.0% by weight, 18.0% by weight, 19.0% by weight, 20% by weight, 21% by weight, 22% by weight, 23% by weight, 24% by weight, and 25.0% by weight relative to the total weight of the composition. The composition contains an effective amount of Brevibacillus laterosporus ferment extract in weight %, 26% by weight, 27% by weight, 28% by weight, 29% by weight, 30% by weight, 31% by weight, 32% by weight, 33% by weight, 34% by weight, 35% by weight, 36% by weight, 37% by weight, 38% by weight, 39% by weight, 40% by weight, 41% by weight, 42% by weight, 43% by weight, 44% by weight, 45% by weight, 46% by weight, 47% by weight, 48% by weight, 49% by weight, 50% by weight, 55% by weight, 60% by weight, 65% by weight, 70% by weight, 75% by weight, 80% by weight, 85% by weight, 90% by weight, 95% by weight, or up to 100% by weight.

[0072] In one embodiment, the odor-suppressing composition containing a fermented extract is formulated into a dry or liquid formulation.

[0073] In one embodiment, the odor-suppressing composition containing the fermented extract is formulated in at least one form selected from the group consisting of loose or compact powder, granules, liquid suspension or solution, spray solution, gel, roll-on, stick, granules, solid soap, and bath bomb, and any combination thereof.

[0074] In one embodiment, the odor-suppressing composition is a composition comprising an effective amount of Brevibacillus laterosporus ferment extract, wherein the Brevibacillus has a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; and non-spore-forming Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109. Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) has a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311, deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785.Brevibacillus laterosporus having a 16S ribosomal RNA sequence with 0% sequence similarity; Brevibacillus laterosporus having a 16S ribosomal RNA sequence with at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; Brevibacillus laterosporus having a 16S ribosomal RNA sequence with at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788 The composition is selected from the group consisting of *Brevibacillus laterosporus* having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of *Brevibacillus laterosporus* ALS321, and *Brevibacillus laterosporus* having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of *Brevibacillus laterosporus* G11_1_1 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787.

[0075] In one embodiment, the inventors unexpectedly observed that an effective amount of Brevibacillus laterosporus ferment extract functions as a detergent.

[0076] One aspect of the present disclosure provides a cleansing composition comprising a Brevibacillus ferment extract and an effective amount of the Brevibacillus ferment extract for preventing, reducing and / or removing sebum and / or dirt from soft surfaces such as body surfaces. In one aspect, the body surface is a human body surface or an animal body surface.

[0077] "Brevibacillus cleansing agent" or "cleansing agent" is understood herein to mean an effective amount of Brevibacillus ferment extract capable of preventing, reducing and / or removing substances associated with sebum (sweat) and other undesirable substances (known in cleansing terminology as "dirt") and / or preventing substances associated with sebum and dirt from adhering to surfaces.

[0078] In one embodiment, the Brevibacillus cleansing agent described herein is a sebum cleansing agent comprising an effective amount of Brevibacillus laterosporus ferment extract, the sebum cleansing agent preventing, reducing and / or removing sebum on body surfaces such as the axillary body surface, skin, feet, hair and scalp, but is not limited. Such a Brevibacillus laterosporus ferment extract can be selected from the group consisting of cell-free supernatant obtained from Brevibacillus laterosporus ferment, whole broth ferment extract obtained from Brevibacillus laterosporus ferment, and any one combination thereof.

[0079] In one embodiment, the composition comprises an effective amount of Brevibacillus laterosporus ferment extract, the extract prevents, reduces and / or removes sebum on the surface, and the composition is selected from the group consisting of personal care compositions.

[0080] In one embodiment, the cleaning composition is provided in amounts of approximately 0.1% by volume, 0.2% by volume, 0.3% by volume, 0.4% by volume, 0.5% by volume, 0.6% by volume, 0.7% by volume, 0.8% by volume, 0.9% by volume, 1% by volume, 2% by volume, 3% by volume, 4% by volume, 5% by volume, 6% by volume, 7% by volume, 8% by volume, 9% by volume, 10% by volume, 11% by volume, 12% by volume, 13% by volume, 14% by volume, 15% by volume, 16% by volume, 17% by volume, 18% by volume, 19% by volume, 20% by volume, 21% by volume, 22% by volume, 23% by volume, 24% by volume, 25% by volume, 26% by volume, and 2% by volume, relative to the total volume of the composition. The composition contains an effective amount of Brevibacillus laterosporus ferment extract in 7 vol%, 28 vol%, 29 vol%, 30 vol%, 31 vol%, 32 vol%, 33 vol%, 34 vol%, 35 vol%, 36 vol%, 37 vol%, 38 vol%, 39 vol%, 40 vol%, 41 vol%, 42 vol%, 43 vol%, 44 vol%, 45 vol%, 46 vol%, 47 vol%, 48 vol%, 49 vol%, 50 vol%, 55 vol%, 60 vol%, 65 vol%, 70 vol%, 75 vol%, 80 vol%, 85 vol%, 90 vol%, 95 vol%, or up to 100 vol%.

[0081] In one embodiment, the cleaning composition is provided in amounts of approximately 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 21% by weight, 22% by weight, 23% by weight, 24% by weight, 25% by weight, 26% by weight, and 2% by weight, relative to the total weight of the composition. The composition contains an effective amount of Brevibacillus laterosporus ferment extract in 7% by weight, 28% by weight, 29% by weight, 30% by weight, 31% by weight, 32% by weight, 33% by weight, 34% by weight, 35% by weight, 36% by weight, 37% by weight, 38% by weight, 39% by weight, 40% by weight, 41% by weight, 42% by weight, 43% by weight, 44% by weight, 45% by weight, 46% by weight, 47% by weight, 48% by weight, 49% by weight, 50% by weight, 55% by weight, 60% by weight, 65% by weight, 70% by weight, 75% by weight, 80% by weight, 85% by weight, 90% by weight, 95% by weight, or up to 100% by weight.

[0082] In one embodiment, the cleansing composition is a sebum cleansing composition comprising an effective amount of Brevibacillus laterosporus ferment extract, wherein the Brevibacillus has a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of non-spore-forming Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2), deposited at the WFDB (Westerdijk Fungal Biodiversity Institute) under number CBS149109; and Brevibacillus laterosporus ALS311, deposited at the WFDB (Westerdijk Fungal Biodiversity Institute) under number CBS149785, with respect to at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1).Brevibacillus laterosporus having a 16S ribosomal RNA sequence with 0% sequence similarity; Brevibacillus laterosporus having a 16S ribosomal RNA sequence with at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; Brevibacillus laterosporus having a 16S ribosomal RNA sequence with at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788 This washing composition is selected from the group consisting of *Brevibacillus laterosporus* having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of *Brevibacillus laterosporus* ALS321, and *Brevibacillus laterosporus* having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of *Brevibacillus laterosporus* G11_1_1 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787.

[0083] The terms “cleaning composition” and “cleaning formulation” refer to a mixture of components used to prevent, reduce, and / or remove unwanted compounds (e.g., dirt or stains) from items or surfaces to be cleaned, such as hair, skin, teeth, and mouth. The composition or formulation may be in the form of a spray, liquid, gel, powder, roll-on, stick, granules, bar soap, or bath bomb.

[0084] In one embodiment, the cleaning composition disclosed herein is a personal care composition.

[0085] It will be apparent that a composition for use according to the present invention may, for example, contain an effective amount of Brevibacillus laterosporus ferment extract in an amount of at least about 0.01% to a maximum of 100% by weight relative to the total weight of the composition.

[0086] In one embodiment, the composition is provided in an amount of at least about 0.01% by weight, 0.02% by weight, 0.03% by weight, 0.04% by weight, 0.05% by weight, 0.06% by weight, 0.07% by weight, 0.08% by weight, 0.09% by weight, 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11.0% by weight, 12.0% by weight, 13.0% by weight, 14.0% by weight, 15.0% by weight, 16.0% by weight, 17.0% by weight, 18.0% by weight, 19.0% by weight, and 20% by weight, relative to the total weight of the composition. Effective amounts of Brevibacillus laterosporus in 0%, 21%, 22%, 23%, 24%, 25.0%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35.0%, 36%, 37%, 38%, 39%, 40.0%, 41%, 42%, 43%, 44%, 45.0%, 46%, 47%, 48%, 49%, 50.0%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or up to 100% by weight. Contains fermented extract of laterosporus.

[0087] It will become even clearer that a composition for use in accordance with the present invention may, for example, contain an effective amount of Brevibacillus laterosporus ferment extract in an amount of at least about 0.01% to a maximum of 100% of the total volume of the composition.

[0088] In one embodiment, the composition is provided in an amount of at least about 0.01% by volume, 0.02% by volume, 0.03% by volume, 0.04% by volume, 0.05% by volume, 0.06% by volume, 0.07% by volume, 0.08% by volume, 0.09% by volume, 0.1% by volume, 0.2% by volume, 0.3% by volume, 0.4% by volume, 0.5% by volume, 0.6% by volume, 0.7% by volume, 0.8% by volume, 0.9% by volume, 1% by volume, 2% by volume, 3% by volume, 4% by volume, 5% by volume, 6% by volume, 7% by volume, 8% by volume, 9% by volume, 10% by volume, 11.0% by volume, 12.0% by volume, 13.0% by volume, 14.0% by volume, 15.0% by volume, 16.0% by volume, 17.0% by volume, 18.0% by volume, 19.0% by volume, and 20% by volume, relative to the total volume of the composition. Effective amounts of Brevibacillus laterosporus in 0 vol%, 21 vol%, 22 vol%, 23 vol%, 24 vol%, 25.0 vol%, 26 vol%, 27 vol%, 28 vol%, 29 vol%, 30.0%, 31 vol%, 32 vol%, 33 vol%, 34 vol%, 35.0 vol%, 36 vol%, 37 vol%, 38 vol%, 39 vol%, 40.0 vol%, 41 vol%, 42 vol%, 43 vol%, 44 vol%, 45.0 vol%, 46 vol%, 47 vol%, 48 vol%, 49 vol%, 50.0 vol%, 55 vol%, 60 vol%, 65 vol%, 70 vol%, 75 vol%, 80 vol%, 85 vol%, 90 vol%, 95 vol%, or up to 100 vol%. Contains fermented extract of laterosporus.

[0089] The personal care compositions of the present invention are not limited to cosmetics (rinse-off cosmetics, leave-on cosmetics), aqueous solutions, emulsions, serums, jellies, patches, lotions, topical moisturizers, creams, pastes, balms, ointments, pomades, gels, liquids, sprays, foams, kits, or any one combination thereof.

[0090] As used herein, the term “rinse-off product” refers to a cosmetic product intended to be removed after application to the skin, hair, or mucous membranes. Rinse-off products include, but are not limited to, shower gels, shampoos, rinse-off conditioners, shower additives (salts, foams, oils, gels), shaving foams, shaving creams, shaving gels, or shaving soaps.

[0091] As used herein, the term “leave-on product” refers to cosmetic products intended to maintain prolonged contact with skin, hair, or mucous membranes. Leave-on products include, but are not limited to, makeup products, face creams, and hair styling gels.

[0092] In one embodiment, the personal care composition of the present invention is formulated for topical administration to the body surface of a human or animal.

[0093] Topical formulations (personal care compositions) for use in the present invention can be in any form suitable for application to the required target, such as creams, lotions, sprays, solutions, gels, ointments, pastes, plasters, cosmetics (paints), bioadhesives, or suspensions, and / or can be prepared to contain liposomes, micelles, and / or microspheres. Such formulations can be used in conjunction with a sealing cover to retain moisture within the formulation when the formulation is applied to the body surface and thereafter, preventing moisture from evaporating from the body surface.

[0094] Topical formulations include those in which the active ingredient is dissolved or dispersed in a dermatological vehicle known in the art (e.g., aqueous or non-aqueous gels, ointments, water-in-oil or oil-in-water emulsions). The components of this type of vehicle may include water, aqueous buffer, non-aqueous solvent (e.g., ethanol, isopropanol, benzyl alcohol, 2-(2-ethoxyethoxy)ethanol, propylene glycol, propylene glycol monolaurate, glycoflor, or glycerol), and oil (e.g., mineral oil such as liquid paraffin, natural or synthetic triglycerides, or silicone oil such as dimethicone). In particular, depending on the properties of the formulation as well as its intended use and application site, the dermatological vehicle used may contain one or more components selected from the following list (for example, components other than water if the formulation is an aqueous gel): solubilizers or solvents (e.g., β-cyclodextrin, e.g., hydroxypropyl β-cyclodextrin, or alcohols or polyols, e.g., ethanol, propylene glycol, or glycerol); thickeners (e.g., hydroxyethylcellulose, hydroxypropylcellulose, carboxymethylcellulose, or carbomer); gelling agents (e.g., polyoxyethylene-polyoxypropylene copolymer); conventional or soft preservatives; and pH buffers (e.g., mixtures of dihydrogen phosphate and hydrogen phosphate, or mixtures of citric acid and hydrogen phosphate).

[0095] The personal care compositions of the present invention may also incorporate carriers that are dermatologically or cosmetically acceptable, which can be any carrier used in the art. Examples include water, lower alcohols, higher alcohols, polyhydric alcohols, monosaccharides, disaccharides, polysaccharides, hydrocarbon oils, fats and oils, waxes, fatty acids, silicone oils, nonionic surfactants, ionic surfactants, silicone surfactants, and aqueous and emulsion mixtures of such carriers.

[0096] The terms “dermatologically acceptable,” “dermatologically acceptable carrier,” or “dermatologically acceptable excipient” are used herein to refer to compounds or compositions that can be incorporated into dermatological or personal care formulations without causing undesirable biological effects or undesirable interactions with other components of the formulation.

[0097] The terms “cosmetic-permissible,” “cosmetic-permissible carrier,” or “cosmetic-permissible excipient” are used herein to refer to compounds or compositions that can be incorporated into cosmetic formulations without causing undesirable biological effects or undesirable interactions with other components of the formulation.

[0098] As used herein, “carrier” or “vehicle” refers to a carrier material suitable for incorporation into a topically applied composition. Useful carriers and vehicles herein include any material known in the art that is non-toxic and does not interact in a detrimental manner with other components of the formulation containing it.

[0099] The term "aqueous" refers to a formulation that contains water or becomes water-containing after being applied to the target tissue (e.g., skin or mucous membrane tissue, but not limited to these).

[0100] The personal care compositions of the present invention may further contain one or more dermatologically or cosmetically acceptable ingredients that are effective for use in known or other personal care products, provided that the optional ingredients are physically and chemically compatible with the essential ingredients described herein, or otherwise do not excessively impair the stability, aesthetics, or performance of the product. Non-limiting examples of such optional components are disclosed in the International Skin Care Ingredient Dictionary, Ninth Edition, 2002 and the CTFA Skin Care Ingredient Handbook, Tenth Edition, 2004.

[0101] In one embodiment, a dermatologically acceptable component is a dermatologically acceptable component that contains from about 10% to about 99.9% by weight, or from about 50% to about 95% by weight, or from about 75% to about 95% by weight of a dermatologically acceptable carrier. Suitable carriers for use in the composition and together therewith include, for example, those used in the formulation of mousses, tonics, gels, and skin moisturizing lotions. Carriers include water; organic oils; silicones such as volatile silicones, amino or non-amino silicone gums or oils and mixtures thereof; mineral oils; vegetable oils such as olive oil, castor oil, rapeseed oil, coconut oil, wheat germ oil, sweet almond oil, avocado oil, macadamia oil, apricot oil, safflower oil, kukui oil, amaranth oil, teri haboku seed oil, lemon oil and mixtures thereof; waxes; and organic compounds such as C2~C , ,

[0102] , 10 , 30 , 10 , 30 alkanes, acetone, methyl ethyl ketone, volatile organic C1~C 12 alcohols, C1~C 20 acids and esters of C1~C8 alcohols such as methyl acetate, butyl acetate, ethyl acetate and isopropyl myristate, dimethoxyethane, diethoxyethane, C 10 ~C 30 fatty alcohols such as lauryl alcohol, cetyl alcohol, stearyl alcohol and behenyl alcohol; C 10 ~C 30 fatty acids such as lauric acid and stearic acid; C 10 ~C 30 fatty amides such as lauric acid diethanolamide; C 10 ~C 30 fatty alkyl esters such as C 10 ~C 30 fatty alkyl benzoates; hydroxypropyl cellulose; and mixtures thereof may be included. In one embodiment, the carrier includes water, fatty alcohols, volatile organic alcohols and mixtures thereof. Those skilled in the art can incorporate other carriers.

[0102] The personal care composition of the present invention may further contain about 0.1% to about 10%, or alternatively about 0.2% to about 5.0%, of a gelling agent that facilitates imparting a desired viscosity to the composition. Non-limiting examples of suitable optional gelling agents include alginates, xanthan gum, crosslinked carboxylic acid polymers; non-neutralized crosslinked carboxylic acid polymers; non-neutralized modified crosslinked carboxylic acid polymers; crosslinked ethylene / maleic anhydride copolymers; non-neutralized crosslinked ethylene / maleic anhydride copolymers (e.g., EMA 81, commercially available from Monsanto); non-neutralized crosslinked alkyl ether / acrylic acid copolymers (e.g., SALCARE® SC90, commercially available from Allied Colloids); non-neutralized crosslinked copolymers of sodium polyacrylate, mineral oil, and PEG-1 trideceth-6 (e.g., SALCARE® SC91, commercially available from Allied Colloids); non-neutralized crosslinked copolymers of methyl vinyl ether and maleic anhydride (e.g., STABILEZE® QM-PVM / MA copolymer, commercially available from International Specialty Products); hydrophobic modified nonionic cellulose polymers; hydrophobic modified ethoxylate urethane polymers (e.g., Union Examples include the UCARE® Polyphobe Series of alkali-swelling polymers commercially available from Carbide, as well as combinations thereof. In this context, the term "non-neutralizing" means that any selected polymer and copolymer gelling agent material contains a non-neutralizing acid monomer.

[0103] A dermatologically or cosmetically acceptable medium may contain fatty substances in a proportion generally of about 10 to about 90% by weight of the total weight of the product, and the fatty phase may contain at least one liquid, solid, or semi-solid fatty substance. Fatty substances include, but are not limited to, oils, waxes, gums, and so-called paste-like fatty substances. Alternatively, the product may be in the form of a stable dispersion such as a water-in-oil or oil-in-water emulsion. Furthermore, personal care products may contain one or more conventional cosmetic or dermatological additives or auxiliaries, such as, but are not limited to, antioxidants, preservatives, fillers, surfactants, UVA and / or UVB sunscreens, fragrances, thickeners, humectants, and anionic, nonionic, or amphoteric polymers, as well as dyes or pigments (colorants).

[0104] A dermatologically acceptable carrier may be a moisturizing formulation containing at least one emulsifier, at least one surfactant, or any combination thereof.

[0105] The personal care compositions described herein may further include materials for skincare active ingredients, including sunscreens, moisturizers, humectants, skin-beneficial substances, adhesion-enhancing agents such as surfactants, occlusive agents, moisture barriers, lubricants, emollients, anti-aging agents, antistatic agents, abrasives, antimicrobial agents, conditioners, scrubs, fragrances, viscosity enhancers, salts, lipids, phospholipids, vitamins, foam stabilizers, pH adjusters, preservatives, suspending agents, silicone oils, silicone derivatives, essential oils, oils, fats, fatty acids, fatty acid esters, fatty alcohols, waxes, polyols, hydrocarbons, and mixtures thereof.

[0106] Any number of dermatologically acceptable ingredients commonly used in skincare products, such as skin conditioning agents and skin colorants, can also be incorporated into this skincare product.

[0107] Skin conditioning agents as defined herein include, but are not limited to, astringents that tighten the skin; scrubs that remove dead skin cells; emollients that promote the maintenance of a smooth, supple, and pliable appearance; humectants that increase the moisture content of the skin surface; occlusive agents that slow the evaporation of water from the skin surface; and various compounds that enhance the appearance of dry or damaged skin, reduce peeling, and restore pliability. Skin conditioning agents are well known in the art (see, for example, Green et al. (International Publication No. 01 / 07009)) and are commercially available from various suppliers. Appropriate examples of skin conditioning agents include, but are not limited to, lactobionic acid, gluconic acid, alpha-hydroxy acid, beta-hydroxy acid, polyols, hyaluronic acid, D,L-panthenol, polysalicylates, vitamin A palmitate, vitamin E acetate, glycerin, sorbitol, silicones, silicone derivatives, lanolin, natural oils, xylitol, fucose, rhamnose, and triglyceride esters. As skin conditioning agents, polysalicylate, propylene glycol (CAS No. 57-55-6, Dow Chemical, Midland, MI), glycerin (CAS No. 56-81-5, Proctor & Gamble Co., Cincinnati, OH), glycolic acid (CAS No. 79-14-1, DuPont Co., Wilmington, DE), lactic acid (CAS No. 50-21-5, Alfa Aesar, Ward Hill, MA), malic acid (CAS No. 617-48-1, Alfa Aesar), citric acid (CAS No. 77-92-9, Alfa Aesar), tartaric acid (CAS No. 133-37-9, Alfa Examples include Alfa Aesar, glucaric acid (CAS No. 87-73-0), galactaric acid (CAS No. 526-99-8), 3-hydroxyvaleric acid (CAS No. 10237-77-1), salicylic acid (CAS No. 69-72-7, Alfa Aesar), and 1,3-propanediol (CAS No. 504-63-2, DuPont Co., Wilmington, DE).Polysalicylic acid can be prepared by the method described in U.S. Patent No. 4,855,483 by White et al., which is incorporated herein by reference. Glucaric acid can be synthesized using the method described by Merbouh et al. (Carbohydr. Res. 336:75-78 (2001)). 3-Hydroxyvaleric acid can be prepared as described in International Publication No. 02 / 012530 by Bramucci.

[0108] In some embodiments, the compositions of the present invention further include, but are not limited to, one or more aqueous carriers, alcohol carriers, antiperspirant active substances, base components, emollients, solidifying agents, hydrates, emulsifiers, solubilizers, fragrances or scents, surfactants, thickeners, salts, and any one combination thereof.

[0109] In one embodiment, the odor-suppressing or cleaning composition described herein contains 30% to 95%, or 40% to 80%, or 50% to 75%, of an aqueous liquid carrier, where other essential and optional compositional components are dissolved, dispersed, or suspended therein.

[0110] The odor-suppressing compositions provided herein include, but are not limited to, granules, powders, liquids, gels, and bar forms including deodorant products, such as roll-on deodorants, spray deodorants, aerosol spray deodorants, powder aerosol spray deodorants, pressed powder deodorants, wax stick deodorants, and alcohol stick deodorants.

[0111] Tables 1A-1B show examples of deodorant model formulations for roll-on, spray, aerosol spray, powder aerosol spray deodorants, pressed powder, wax stick, and alcohol stick deodorants.

[0112] [Table 1A]

[0113] [Table 1B]

[0114] In one embodiment, the odor-suppressing and cleaning compositions provided herein include a fragrance and / or scent. Any available fragrance / scent may be used in the personal care compositions and methods herein.

[0115] There are no restrictions on the types of compositions in which fragrances can be incorporated. They may be included in compositions in the form of, for example, sprays, liquids, gels, powders, roll-ons, sticks, granules, solid soaps, or bath bombs.

[0116] Fragrance components can be incorporated into a composition in physical form by adding them, for example, as liquids, solid particles, and / or microcapsules, using methods known in the art.

[0117] Methods for providing odor suppression The compositions described herein can be used in methods for providing odor suppression.

[0118] Methods are provided for preventing and / or reducing odors from the body surface of humans or animals, such as the skin, scalp (hair), and feet.

[0119] One embodiment provides a method for preventing and / or reducing body odor, comprising contacting the body surface with an effective amount of Brevibacillus laterosporus ferment extract.

[0120] The reduction of malodorous odors can be measured by human sensory observation, such as smelling the surface or solution, or by analytical measurement of malodorous compounds, including but not limited to gas chromatography-mass spectrometry (GC / MS), gas chromatography-mass spectrometry with solid-phase trace extraction (GC / MS-SPME), or gas chromatography-olfactometry (GC-O).

[0121] The surface can be brought into contact with an effective amount of Brevibacillus laterosporus ferment extract in the deodorizing composition format.

[0122] In some embodiments, the body surface can be brought into contact with an effective amount of Brevibacillus laterosporus ferment extract or a composition containing an effective amount of Brevibacillus laterosporus for any desired duration or duration sufficient to prevent and / or reduce odor on the surface.

[0123] In one embodiment, the Disclosure provides a method for preventing, reducing, or removing an odor from a surface, comprising contacting the surface with an effective amount of Brevibacillus ferment extract or a composition comprising an effective amount of Brevibacillus ferment extract, and optionally rinsing the composition off the item.

[0124] In one embodiment, the method is a method for preventing or reducing malodor from a body surface, comprising the step of applying to the body surface an effective amount of Brevibacillus laterosporus ferment extract or a composition comprising an effective amount of Brevibacillus laterosporus ferment extract, wherein the extract prevents and / or reduces the malodor from the body surface.

[0125] In one embodiment, the method is a method for preventing or reducing body odor, comprising the step of applying an effective amount of Brevibacillus laterosporus ferment extract or a composition containing an effective amount of Brevibacillus laterosporus ferment extract to a body surface, preferably the axillary skin, wherein the extract prevents and / or reduces the body odor on the body surface. In one embodiment, the Brevibacillus laterosporus ferment extract or the composition containing Brevibacillus laterosporus is applied to the body surface of a human or animal. In one embodiment, the Brevibacillus laterosporus ferment extract or the composition containing Brevibacillus laterosporus is applied to the axillary region of the body surface of a human or animal.

[0126] In one embodiment, a fermented extract of Brevibacillus laterosporus or a composition containing Brevibacillus laterosporus is applied to the axillary body surface (the axillary region of the body or the skin surface of the armpit), skin, feet, hair and scalp.

[0127] In one embodiment, the present method is a method for preventing or reducing body odor, comprising the step of applying to the body surface an effective amount of Brevibacillus laterosporus ferment extract or a composition containing an effective amount of Brevibacillus laterosporus ferment extract, wherein the application step comprises applying to the body surface a composition containing an effective amount of Brevibacillus laterosporus ferment extract in an effective amount of 0.01% to 100% by weight or an effective amount of Brevibacillus laterosporus ferment extract in

[0128] In one embodiment, the method is a method for preventing or reducing body odor, and the composition is used in amounts of about 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 21% by weight, 22% by weight, 23% by weight, 24% by weight, and 25% by weight relative to the total weight of the composition. The method comprises the step of applying a composition containing an effective amount of Brevibacillus laterosporus ferment extract in weight %, 26% by weight, 27% by weight, 28% by weight, 29% by weight, 30% by weight, 31% by weight, 32% by weight, 33% by weight, 34% by weight, 35% by weight, 36% by weight, 37% by weight, 38% by weight, 39% by weight, 40% by weight, 41% by weight, 42% by weight, 43% by weight, 44% by weight, 45% by weight, 46% by weight, 47% by weight, 48% by weight, 49% by weight, 50% by weight, 55% by weight, 60% by weight, 65% by weight, 70% by weight, 75% by weight, 80% by weight, 85% by weight, 90% by weight, 95% by weight, or up to 100% by weight, to the body surface.

[0129] In one embodiment, the present method is a method for preventing or reducing body odor, wherein the composition is present in an amount of approximately 0.1% by volume, 0.2% by volume, 0.3% by volume, 0.4% by volume, 0.5% by volume, 0.6% by volume, 0.7% by volume, 0.8% by volume, 0.9% by volume, 1% by volume, 2% by volume, 3% by volume, 4% by volume, 5% by volume, 6% by volume, 7% by volume, 8% by volume, 9% by volume, 10% by volume, 11% by volume, 12% by volume, 13% by volume, 14% by volume, 15% by volume, 16% by volume, 17% by volume, 18% by volume, 19% by volume, 20% by volume, 21% by volume, 22% by volume, 23% by volume, 24% by volume, and 25% by volume relative to the total volume of the composition. The method comprises the step of applying a composition containing an effective amount of Brevibacillus laterosporus ferment extract in volume %, 26 volume%, 27 volume%, 28 volume%, 29 volume%, 30 volume%, 31 volume%, 32 volume%, 33 volume%, 34 volume%, 35 volume%, 36 volume%, 37 volume%, 38 volume%, 39 volume%, 40 volume%, 41 volume%, 42 volume%, 43 volume%, 44 volume%, 45 volume%, 46 volume%, 47 volume%, 48 volume%, 49 volume%, 50 volume%, 55 volume%, 60 volume%, 65 volume%, 70 volume%, 75 volume%, 80 volume%, 85 volume%, 90 volume%, 95 volume%, or up to 100 volume%, to the body surface.

[0130] In one embodiment, the Brevibacillus laterosporus ferment extract for use in the method herein is selected from the group consisting of cell pellet extracts obtained from Brevibacillus laterosporus ferment, cell-free supernatants obtained from Brevibacillus laterosporus ferment, whole broth ferment extracts obtained from Brevibacillus laterosporus ferment, and any one combination thereof.

[0131] In one embodiment, the Brevibacillus laterosporus ferment extract for use in the method herein is a Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; and a non-spore-forming Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109. Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2) has a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311, deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785.Brevibacillus laterosporus having a 16S ribosomal RNA sequence with 0% sequence similarity; Brevibacillus laterosporus having a 16S ribosomal RNA sequence with at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149786; Brevibacillus laterosporus having a 16S ribosomal RNA sequence with at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788 Obtained from a fermented product of Brevibacillus laterosporus selected from the group consisting of Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G11_1_1 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787.

[0132] General definition All patent and non-patent literature disclosures cited herein are incorporated herein by reference in their entirety.

[0133] This disclosure uses numerous terms and abbreviations. Unless otherwise specified, the following definitions apply.

[0134] As used herein, the articles “a,” “an,” and “the” preceding an element or component of the present invention are intended to be non-limiting with respect to the number of instances (i.e., occurrences) of that element or component. Therefore, “a,” “an,” and “the” should be read as including one or at least one, and the singular form of an element or component also includes the plural form unless it specifically implies that its number is singular.

[0135] Where quantities, concentrations, or other values ​​or parameters are given as a range, a preferred range, or a list of preferred higher and preferred lower values, this should be understood to specifically disclose any range formed by any pair of upper or preferred higher values ​​of any range and lower or preferred lower values ​​of any range, regardless of whether the ranges are disclosed separately. Where a range of numerical values ​​is enumerated herein, unless otherwise specified, that range is intended to include its endpoint and all integers and fractions within that range. The range of the present invention is not intended to be limited to any specific values ​​enumerated when defining a range.

[0136] The use of numerical values ​​within the various ranges specified in this application is described as approximations, as if preceded by the term “approximately” before either the minimum or maximum value within the specified range, unless otherwise explicitly indicated. In this form, a small variation above or below the specified range can be used to achieve substantially the same results as values ​​within that range. The disclosure of these ranges is also intended to include a continuous range encompassing each and every value between the minimum and maximum values. As used herein, the term “approximately” modifying the amount of components or reactants used means variations in quantity that may occur, for example, through typical weighing and liquid handling procedures used in the real world to prepare concentrates or solutions for use; through accidental errors in these procedures; or through differences in the manufacture, source, or purity of components used to prepare a composition or to carry out the method. The term “approximately” also encompasses different quantities resulting from different equilibrium conditions for the resulting composition from a particular initial mixture. Whether modified by the term “approximately” or not, the claims include quantitative equivalents.

[0137] The term "aqueous" as used in the phrases "aqueous composition" and "aqueous environment" refers to a composition consisting of at least 50% water. An aqueous composition may contain at least 50%, 60%, 70%, 80%, 90%, 95%, 97%, 98%, or 99% water.

[0138] As used herein, the term “biological contaminant” means one or more undesirable and / or pathogenic biological entities, including, but not limited to, microorganisms, spores, viruses, prions, and mixtures thereof.

[0139] As used herein, the term “including” means the presence of a specific feature, integer, process, or component referred to in the claims, but does not exclude the presence or addition of one or more other features, integers, processes, components, or groups thereof. The term “including” includes embodiments that are essentially comprised of the terms “essentially comprised of” and “consisting of.” Similarly, the term “essentially comprised of” is intended to include embodiments that are essentially comprised of.

[0140] As used herein, the terms “cell lysate” or “lysate” refer to microbial cells lysed by any suitable means. The terms “cell lysate” or “lysate” traditionally refer to materials obtained by dissolving or dissolving living cells through a phenomenon known as lysis, thereby releasing naturally occurring intracellular biocomponents within the cells of the microorganism of interest. For the purposes of this disclosure, the term “lysate” is used without preference for referring only to whole cell lysates or fragments thereof obtained through the lysis of the microorganism of interest. Therefore, the lysates used are formed in whole or in part from intracellular biocomponents as well as components of the cell wall and cell membrane. The lysates used in the present invention may be whole cell lysates or fractions thereof obtained through the lysis of the microorganism of interest. This cell lysis can be achieved by any suitable means or any method known in the art. It can be achieved by, but is not limited to, osmotic shock, heat shock, ultrasonication, sonication, homogenization, shear, chemical dissolution, or centrifugal mechanical stress. In some embodiments, cell fragments are removed from the cell lysate before use. In some embodiments, the cell lysate is filtered before use.

[0141] As used herein, "cleaning" means applying to a surface for the purpose of cleaning.

[0142] The term "cleaned surface" refers to a surface where the stain removal percentage is at least 10%, preferably at least 15%, 20%, 25%, 30%, 35%, or 40% of the soiled surface.

[0143] As used herein, the terms “embodiments” or “disclosure” are not intended to be limiting, but rather apply generally to either the embodiments defined in the claims or those described herein. These terms are used interchangeably herein.

[0144] As used herein, the term “excipient” refers to an inert substance used in a formulation as a carrier for the active ingredient. Excipients may be used to stabilize the active ingredient in the formulation, such as for storage stability. Excipients may also be used to increase the volume of a formulation containing the active ingredient.

[0145] As used herein, the term “effective amount” refers to an amount sufficient to obtain the desired effect. When used in combination with Brevibacillus ferment extract, the term “effective amount” refers to the amount of Brevibacillus ferment extract required in a particular composition to achieve the desired level of cleaning and / or odor-suppressing activity. Such an effective amount is readily verifiable by those skilled in the art and depends on many factors, including the specific Brevibacillus ferment extract used, the odor-suppressing or cleaning application, the specific composition of the odor-suppressing or cleaning composition, and the required form of the composition (e.g., spray, liquid, gel, powder, roll-on, stick, granules, solid soap, and bath bomb).

[0146] As used herein, the terms “fragrance” or “scent” include raw materials and compositions, accords, scents, and oils, such as essential oils. A wide variety of chemical substances, including compounds such as aldehydes, ketones, and esters, are known for fragrance (i.e., scent) applications. Natural vegetable and animal oils and extracts, containing complex mixtures of various chemical components, are also known to be used as fragrances.

[0147] Fragrances may be blends of volatile compounds with different volatility levels, which can bind to receptors in the nose and thus have a scent or odor, usually pleasant. These compounds are also known as deodorants or fragrances. Most fragrances have a molar weight of up to about 200 g / mol, and sometimes up to about 300 g / mol. The larger the molecule, the less volatile it is perceived by the human nose. The volatility of a compound describes how easily it vaporizes by evaporation or boiling. Fragrance compounds evaporate by evaporation at room temperature and atmospheric pressure, depending on their volatility. Volatility is often described using vapor pressure or boiling point, with high vapor pressure or low boiling point indicating high volatility. The volatility of a compound is related to its molecular weight, but other factors such as structure and polarity also play a role, as do the interactions between fragrance compounds.

[0148] As used herein, the terms “its metabolite,” “metabolites of microorganisms suitable for use in the present invention,” or “metabolite-active substances” are interchangeable and refer to any substance derived from the metabolism of a microorganism suitable for use in the present invention.

[0149] As used herein, the term “soluble metabolite” refers to one or more metabolites present in the supernatant (fermentation supernatant) of a cell culture from which cells have been removed. In one embodiment, the cells are removed by centrifugation. In one embodiment, the supernatant is filtered. It will be apparent that the supernatant may be used directly in the formulation of the present invention, or that one or more metabolites may be isolated from the supernatant by any suitable means before use.

[0150] As used herein, the terms “neutralize” or “neutralize” refer to the ability of a compound or product to reduce or eliminate malodorous compounds. Odor neutralization may be partial, affecting only some or only a portion of malodorous compounds in a given situation. Malodorous compounds may be neutralized by chemical reactions to produce new chemical substances, by sequestration, by chelation, by association, or by any other interaction that makes malodorous compounds less odorous or non-odorous. Odor neutralization may be distinguished from odor masking or odor blocking due to a change in the malodorous compound, as opposed to a change in the ability to perceive the odor without any corresponding change in the state of the malodorous compound.

[0151] As used herein, the terms “reduce,” “reduce,” and their grammatical variations relating to a particular feature, characteristic, feature, biological process, or phenomenon mean a decrease in that particular feature, characteristic, feature, biological process, or phenomenon. This feature, characteristic, feature, biological process, or phenomenon may be reduced by more than 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 100%, or more than 100%.

[0152] The terms "weight %", "weight percent (wt.%)", and "weight-weight percent (% w / w)" are used interchangeably herein. Weight percent refers to the percentage of a material by mass contained in a composition, mixture, solution, or product.

[0153] The terms "volume %" and "volume percentage" are used interchangeably herein. Volume percentage refers to the percentage of a material by volume contained in a composition, mixture, solution, or product.

[0154] The term "16S rRNA" or "16S ribosomal RNA" refers to the rRNA that constitutes the small subunit of the ribosome in prokaryotes. In bacteria, this sequence can be used to identify and characterize operational taxa.

[0155] The term "ITS" or "internal transcription spacer" refers to regions within ribosome transcripts that are cleaved and degraded during maturation. These sequences can be used for phylogenetic analysis and / or identification of fungi or yeasts.

[0156] The terms “percent (%) sequence identity” or “percent (%) sequence similarity,” as used herein in relation to a reference sequence, are defined as the percentage of nucleotide residues in a candidate sequence that are identical to residues in a reference polynucleotide sequence after the sequence has been optimally aligned by inserting gaps as necessary to maximize sequence identity %.

[0157] As used herein, a microbial "strain" refers to a microorganism (such as a bacterium or fungus) that remains genetically unchanged even as it grows or multiplies. This encompasses diversity within the same microorganism.

[0158] As used herein, the term “biologically pure strain” means a strain that does not contain other microbial strains in amounts sufficient to prevent strain replication or to be detected by conventional techniques. “Isolated,” as used herein in reference to the organisms and cultures described herein, includes not only biologically pure strains but also any culture of an organism that is grown or maintained in a manner different from that found in nature.

[0159] As used herein, the terms “probiotics” or “probiotic microorganisms” are interchangeable herein and refer to living microorganisms (including, for example, bacteria or yeasts) that, when administered in sufficient quantities (topically or orally), have a beneficial effect on a host organism, i.e., by providing one or more demonstrable benefits to the host organism, such as a reduction in excessive dandruff. There are no lower or upper limits on the use of probiotics, but the daily dose should be at least 10 6 ~10 12 Preferably at least 10 6 ~10 10Preferably 10 8 ~10 9 It has been suggested that CFU is effective in obtaining beneficial effects in the target population.

[0160] The terms “sequence identity” or “sequence similarity,” as used herein, mean that two polynucleotide sequences (i.e., a candidate sequence and a reference sequence) are identical (i.e., 100% sequence identity) or similar (i.e., similar on a nucleotide-to-nucleotide basis) over the entire length of the candidate sequence. When the candidate sequence and the reference sequence are optimally aligned, the candidate sequence may contain additions or deletions (i.e., gaps) compared to the reference sequence (which does not include additions or deletions). Optimal alignment of sequences to determine sequence identity can be performed using any publicly available local alignment algorithm known in the art (e.g., ALIGN or Megalign (DNASTAR)), or by scrutiny.

[0161] As used herein, “surface” means any surface, including hard, soft, and porous surfaces. As used herein, the term “hard surface” means, but is not limited to, floors, tables, walls, roofs, metals, glass, ceramics, wood, minerals (rocks, stones, marble, granite), aggregates, such as concrete, plastics, composite materials, hard rubber materials, and plaster, and any object having a hard surface, such as automobiles, ship hulls, dishes (tableware), medical equipment, pipes, reservoirs, or holding tanks. Hard surface materials may be finished with enamels and paints. Hard surfaces are found, for example, in kitchen tiles, bathroom tiles, water treatment and storage equipment and tanks; dairy and food processing equipment and facilities; medical equipment and facilities, such as surgical instruments and permanent and temporary implants; and industrial pharmaceutical equipment and plants. The term “hard surface” also includes the surface of a flexible but hard object, such as the inside of a bendable tube and supply line or the surface of a deformable holding tank or container.

[0162] Soft surfaces include, for example, the body surface such as the axillary body surface, skin, feet, hair, and scalp. Soft surfaces include the body surfaces of humans and animals.

[0163] Porous surfaces can also be found in certain ceramics and membranes used for filtration. Other surfaces include, but are not limited to, ship hulls and swimming pools. Other surfaces may be biological surfaces such as skin, keratin, or organs.

[0164] The term "surfactant" refers to any compound that is generally recognized in the art as having surface-active properties. Common examples of surfactants include anionic compounds, cationic compounds, nonionic compounds, and zwitterionic compounds, which are further described herein.

[0165] Throughout this specification, all numerical upper limits are intended to include all lower numerical limits as if such lower numerical limits were explicitly stated herein. Throughout this specification, all numerical lower limits will include all higher numerical limits as if such higher numerical limits were explicitly stated herein. Throughout this specification, all numerical ranges will include all narrower numerical ranges that fall within such wider numerical ranges as if such narrower numerical ranges were all explicitly stated herein.

[0166] Unless otherwise defined herein, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention pertains.

[0167] Non-limiting examples of compositions and methods disclosed herein include:

[0168] 1. An odor-suppressing composition comprising an effective amount of Brevibacillus laterosporus ferment extract, wherein the extract prevents and / or reduces body odor.

[0169] 2. The odor-suppressing composition of Embodiment 1, wherein the Brevibacillus laterosporus ferment extract is selected from the group consisting of cell pellet extract obtained from Brevibacillus laterosporus ferment, cell-free supernatant obtained from Brevibacillus laterosporus ferment, whole broth ferment extract obtained from Brevibacillus laterosporus ferment, and any one combination thereof.

[0170] 3. The odor-suppressing composition of Embodiment 1, wherein the body surface is selected from the group consisting of the axillary region of the body, skin, feet, hair, and scalp.

[0171] 3b. The odor-suppressing composition of Embodiment 1, wherein a fermented extract of Brevibacillus laterosporus or a composition containing a fermented extract is formulated in a dry formulation or a liquid formulation.

[0172] 3c. The odor-suppressing composition of Embodiment 1, wherein a fermented extract of Brevibacillus laterosporus or a composition containing a fermented extract is formulated in at least one form selected from the group consisting of loose or compact powder, granules, liquid suspension or solution, spray solution, gel, roll-on, stick, granules, solid soap, and bath bomb, or any one combination thereof.

[0173] 4. The odor-suppressing composition of Embodiment 1, wherein the composition is a personal care or cosmetic composition.

[0174] 5. A personal care composition of Embodiment 4, wherein the composition is a deodorizing composition.

[0175] 6. The deodorizing composition of Embodiment 5, wherein the composition is a deodorizing stick, a deodorizing spray, a deodorizing powder, or a roll-on deodorizer.

[0176] 6b. The deodorizing stick composition of Embodiment 5, wherein the stick is a wax stick or an alcohol stick.

[0177] 6c. The deodorizing spray composition of Embodiment 5, wherein the spray is an aerosol spray or a powder aerosol spray.

[0178] 7. A deodorizing composition for preventing or reducing body odor, comprising an effective amount of Brevibacillus laterosporus ferment extract as a deodorizing active ingredient, wherein the effective amount of extract prevents and / or reduces body odor, and the ingredient is incorporated into a deodorizing vehicle.

[0179] 7b. A deodorizing composition of Embodiment 5 or Embodiment 7, wherein the composition is in the form of a spray, liquid, gel, powder, roll-on, stick, granules, solid soap, or bath bomb.

[0180] 8. A deodorizing composition comprising i) an effective amount of Brevibacillus laterosporus ferment extract as a deodorizing active ingredient, ii) a liquid carrier deodorizing active substance, and optionally iii) a fragrance.

[0181] 9.0.01% to 100% by weight of a fermented extract of Brevibacillus laterosporus, the odor-suppressing composition of Embodiment 1.

[0182] 9b. Approximately 0.1 volume%, 0.2 volume%, 0.3 volume%, 0.4 volume%, 0.5 volume%, 0.6 volume%, 0.7 volume%, 0.8 volume%, 0.9 volume%, 1 volume%, 2 volume%, 3 volume%, 4 volume%, 5 volume%, 6 volume%, 7 volume%, 8 volume%, 9 volume%, 10 volume%, 11 volume%, 12 volume%, 13 volume%, 14 volume%, 15 volume%, 16 volume%, 17 volume%, 18 volume%, 19 volume%, 20 volume%, 21 volume%, 22 volume%, 23 volume%, 24 volume%, 25 volume%, 26 volume%, 27 volume%, 2 The odor-suppressing composition of Embodiment 1, comprising an effective amount of Brevibacillus laterosporus ferment extract in 8 vol%, 29 vol%, 30 vol%, 31 vol%, 32 vol%, 33 vol%, 34 vol%, 35 vol%, 36 vol%, 37 vol%, 38 vol%, 39 vol%, 40 vol%, 41 vol%, 42 vol%, 43 vol%, 44 vol%, 45 vol%, 46 vol%, 47 vol%, 48 vol%, 49 vol%, 50 vol%, 55 vol%, 60 vol%, 65 vol%, 70 vol%, 75 vol%, 80 vol%, 85 vol%, 90 vol%, 95 vol%, or up to 100 vol%.

[0183] 9c. About 0.1% by weight, 0.2% by weight, 0.3% by weight, 0.4% by weight, 0.5% by weight, 0.6% by weight, 0.7% by weight, 0.8% by weight, 0.9% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, 10% by weight, 11% by weight, 12% by weight, 13% by weight, 14% by weight, 15% by weight, 16% by weight, 17% by weight, 18% by weight, 19% by weight, 20% by weight, 21% by weight, 22% by weight, 23% by weight, 24% by weight, 25% by weight, 26% by weight, 27% by weight, 2 An odor-suppressing composition of Embodiment 1, comprising an effective amount of Brevibacillus laterosporus ferment extract in 8% by weight, 29% by weight, 30% by weight, 31% by weight, 32% by weight, 33% by weight, 34% by weight, 35% by weight, 36% by weight, 37% by weight, 38% by weight, 39% by weight, 40% by weight, 41% by weight, 42% by weight, 43% by weight, 44% by weight, 45% by weight, 46% by weight, 47% by weight, 48% by weight, 49% by weight, 50% by weight, 55% by weight, 60% by weight, 65% by weight, 70% by weight, 75% by weight, 80% by weight, 85% by weight, 90% by weight, 95% by weight, or up to 100% by weight.

[0184] 10. Any one of Embodiments 1 to 9, further comprising an agent selected from the group consisting of an aqueous carrier, an alcohol carrier, an antiperspirant active substance, a base component, a skin emollient, a solidifying agent, a wettable agent, an emulsifier, a solubilizer, a fragrance, a surfactant, a thickener, a salt, and any one combination thereof.

[0185] 10b. Brevibacillus laterosporus has a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G2 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; non-spore-forming Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109 Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2); Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; Westerdijk Fungal Biodiversity At least 97% of the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited with the World Food Database (WFDB) under the number CBS149786 were compared.Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing 0% sequence similarity; Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787 A single odor-suppressing composition according to one of Embodiments 1 to 10, selected from the group consisting of Brevibacillus laterosporus, which has a 16S ribosomal RNA sequence exhibiting at least 97.0% sequence similarity to the 16S ribosomal RNA sequence of laterosporus)G11_1_1 (Sequence ID 1).

[0186] 11. A method for preventing or reducing malodorous odors from a body surface, comprising the step of applying one of the compositions from Embodiments 1 to 10 to a body surface.

[0187] 11b. A method for preventing or reducing body odor, comprising the step of applying an effective amount of a fermented extract of Brevibacillus laterosporus to a body surface, preferably axillary skin, wherein the extract prevents and / or reduces the body odor on the body surface.

[0188] 12. A method according to Embodiment 11, wherein the composition is applied to the body surface of a human or animal.

[0189] 12b. A method according to Embodiment 12, wherein the composition is applied to the axillary region of the body surface of a human or animal.

[0190] 13. A method according to Embodiment 11, wherein the composition is applied to a human foot.

[0191] 14. The application process is approximately 0.1 volume%, 0.2 volume%, 0.3 volume%, 0.4 volume%, 0.5 volume%, 0.6 volume%, 0.7 volume%, 0.8 volume%, 0.9 volume%, 1 volume%, 2 volume%, 3 volume%, 4 volume%, 5 volume%, 6 volume%, 7 volume%, 8 volume%, 9 volume%, 10 volume%, 11 volume%, 12 volume%, 13 volume%, 14 volume%, 15 volume%, 16 volume%, 17 volume%, 18 volume%, 19 volume%, 20 volume%, 21 volume%, 22 volume%, 23 volume%, 24 volume%, 25 volume%, 26 volume%, 27 volume%, 28 Brevibacillus laterosporus in volume %, 29 volume%, 30 volume%, 31 volume%, 32 volume%, 33 volume%, 34 volume%, 35 volume%, 36 volume%, 37 volume%, 38 volume%, 39 volume%, 40 volume%, 41 volume%, 42 volume%, 43 volume%, 44 volume%, 45 volume%, 46 volume%, 47 volume%, 48 volume%, 49 volume%, 50 volume%, 55 volume%, 60 volume%, 65 volume%, 70 volume%, 75 volume%, 80 volume%, 85 volume%, 90 volume%, 95 volume%, or up to 100 volume% laterosporus) fermented product extract, or about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6% by weight, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 2 A method of any one of embodiments 11 to 13, comprising applying a fermented extract of Brevibacillus laterosporus in an amount of 7% by weight, 28% by weight, 29% by weight, 30% by weight, 31% by weight, 32% by weight, 33% by weight, 34% by weight, 35% by weight, 36% by weight, 37% by weight, 38% by weight, 39% by weight, 40% by weight, 41% by weight, 42% by weight, 43% by weight, 44% by weight, 45% by weight, 46% by weight, 47% by weight, 48% by weight, 49% by weight, 50% by weight, 55% by weight, 60% by weight, 65% by weight, 70% by weight, 75% by weight, 80% by weight, 85% by weight, 90% by weight, 95% by weight, or up to 100% by weight, to the body surface.

[0192] 14b. The application process is approximately 0.1 volume%, 0.2 volume%, 0.3 volume%, 0.4 volume%, 0.5 volume%, 0.6 volume%, 0.7 volume%, 0.8 volume%, 0.9 volume%, 1 volume%, 2 volume%, 3 volume%, 4 volume%, 5 volume%, 6 volume%, 7 volume%, 8 volume%, 9 volume%, 10 volume%, 11 volume%, 12 volume%, 13 volume%, 14 volume%, 15 volume%, 16 volume%, 17 volume%, 18 volume%, 19 volume%, 20 volume%, 21 volume%, 22 volume%, 23 volume%, 24 volume%, 25 volume%, 26 volume%, 27 volume%, 2 8 vol%, 29 vol%, 30 vol%, 31 vol%, 32 vol%, 33 vol%, 34 vol%, 35 vol%, 36 vol%, 37 vol%, 38 vol%, 39 vol%, 40 vol%, 41 vol%, 42 vol%, 43 vol%, 44 vol%, 45 vol%, 46 vol%, 47 vol%, 48 vol%, 49 vol%, 50 vol%, 55 vol%, 60 vol%, 65 vol%, 70 vol%, 75 vol%, 80 vol%, 85 vol%, 90 vol%, 95 vol%, or up to 100 vol%, of Brevibacillus laterosporus. Laterosporus) ferment extract, or approximately 0.1 vol%, 0.2 vol%, 0.3 vol%, 0.4 vol%, 0.5 vol%, 0.6 vol%, 0.7 vol%, 0.8 vol%, 0.9 vol%, 1 vol%, 2 vol%, 3 vol%, 4 vol%, 5 vol%, 6 vol%, 7 vol%, 8 vol%, 9 vol%, 10 vol%, 11 vol%, 12 vol%, 13 vol%, 14 vol%, 15 vol%, 16 vol%, 17 vol%, 18 vol%, 19 vol%, 20 vol%, 21 vol%, 22 vol%, 23 vol%, 24 vol%, 25 vol%, 26 vol%, 2 A method of any one of Embodiments 11 to 13, comprising applying a Brevibacillus laterosporus ferment extract in an amount of 7 vol%, 28 vol%, 29 vol%, 30 vol%, 31 vol%, 32 vol%, 33 vol%, 34 vol%, 35 vol%, 36 vol%, 37 vol%, 38 vol%, 39 vol%, 40 vol%, 41 vol%, 42 vol%, 43 vol%, 44 vol%, 45 vol%, 46 vol%, 47 vol%, 48 vol%, 49 vol%, 50 vol%, 55 vol%, 60 vol%, 65 vol%, 70 vol%, 75 vol%, 80 vol%, 85 vol%, 90 vol%, 95 vol%, or up to 100 vol%, to the body surface.

[0193] 15. Any one of embodiments 11 to 14, wherein the Brevibacillus laterosporus ferment extract is selected from the group consisting of cell pellet extract obtained from Brevibacillus laterosporus ferment, cell-free supernatant obtained from Brevibacillus laterosporus ferment, whole broth ferment extract obtained from Brevibacillus laterosporus ferment, and any one combination thereof.

[0194] 16. Brevibacillus laterosporus, which has a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus G2 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; non-spore-forming Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109 Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2); Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; Westerdijk Fungal Biodiversity At least 97% of the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited with the World Food Database (WFDB) under the number CBS149786 were compared.Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing 0% sequence similarity; Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; and Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787 A method selected from any one of embodiments 11 to 14, comprising Brevibacillus laterosporus having a 16S ribosomal RNA sequence exhibiting at least 97.0% sequence similarity to the 16S ribosomal RNA sequence of laterosporus)G11_1_1 (Sequence ID 1). [Examples]

[0195] In the following embodiments, unless otherwise specified, parts and percentages are by weight, and degrees are in Celsius. It should be understood that these embodiments illustrate embodiments of the present disclosure, but are presented for illustrative purposes only. From the above discussion and these embodiments, those skilled in the art can make various changes and modifications to the present disclosure to adapt it to various uses and conditions. Such modifications are intended to be included within the scope of the appended claims.

[0196] In this specification, the following abbreviations correspond to the following units of measurement, methods, properties, or compounds: "sec" or "s" means seconds, "min" means minutes, "h" or "hr" means hours, "mL" means milliliters, "mL" means milliliters, "L" means liters, "mM" means millimolar concentration, "M" means molar concentration, "mmol" means millimoles, "uM" or "μM" means micromoles, "ppm" means parts per million, "wt" means weight, "wt%" means weight percent, "g" means grams, "mg" means milligrams, "mg" means micrograms, "ng" means nanograms, "conc." means concentration, and "Trt" means treatment.

[0197] Example 1 Brevibacillus strain Suitable Brevibacillus laterosporus for use in this invention include, but are not limited to, Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain G2 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149108; and non-spore-forming Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149109. Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus strain A8.11 (derived from Brevibacillus laterosporus G2); Brevibacillus laterosporus having a 16S ribosomal RNA sequence that shows at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS311 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149785; Westerdijk Fungal Biodiversity At least 97% of the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS317 deposited with the World Food Database (WFDB) under the number CBS149786 were compared.Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing 0% sequence similarity; and Brevibacillus laterosporus having a 16S ribosomal RNA sequence showing at least 97.0% sequence similarity to the 16S ribosomal RNA sequence (SEQ ID NO: 1) of Brevibacillus laterosporus ALS321 deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149788; Brevibacillus laterosporus deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under number CBS149787 Examples include *Brevibacillus laterosporus* and any combination thereof, which possess a 16S ribosomal RNA sequence showing at least 97.0% sequence similarity to the 16S ribosomal RNA sequence of *G11_1_1* (Sequence ID 1).

[0198] Brevibacillus laterosporus strains G2 and G11_1_1 were isolated and serially diluted from a facial skin microbiome library prepared by swabbing the surface of facial skin and transferring it to phosphate-buffered saline. The serial dilutions were placed on petri dishes containing TSA (17 g tryptone, 3 g soytone, 5 g NaCl, 2.5 g dipotassium phosphate, 2.5 g glucose, and 15 g agar per liter of distilled water). The plates were then incubated aerobically at 33°C until colonies were visible. The isolated colonies were used as a source for PCR reactions using standard protocols. The phylogenetic identity of Brevibacillus laterosporus strain G2 was determined by sequencing the 16S region using primer set A (SEQ ID NO: 2) (where "M" is adenine or cytosine nucleotide) and primer set B (SEQ ID NO: 3).

[0199] Isolation of endospore-deficient strains Brevibacillus laterosporus is a rod-shaped endospore-forming bacterium. However, the presence of endospores in the final product or waste from industrial manufacturing is undesirable. Therefore, it is preferable that Brevibacillus laterosporus-producing strains are unable to form endospores.

[0200] Removal of endospore production was achieved using a homologous recombination vector targeting the stage II sporogenesis protein E (spoIIE) gene (SEQ ID NO: 4) of Brevibacillus laterosporus. The spoIIE locus in Bacillus subtilis is required for normal endospore formation through activation of the transcription factor sigma F (Barak I., Behari J., Olmedo G., Guzman P., Brown D., Castro E., Walker D., Westpheling J., & Youngman P. (1996) Structure and function of the Bacillus SpoIIE protein and its localization to sites of sporulation septum assembly. Mol Microbiol. 19(5):1047-60.). A truncated spoIIE gene was synthesized by removing the first 600 bp starting with the start codon (SEQ ID NO: 5; Integrated DNA Technologies, Coralville, Iowa). The truncated gene was assembled into an insertion vector (Leenhouts, KJ, et al., 1991, Plasmid, 26(1), 55-66; Maguin, E., et al., 1992, J Bacteriol, 174(17), 5633-5638).

[0201] The success of integration resulting in cleavage of the spoIIE gene was determined by PCR using primer sets A2 (SEQ ID NO: 6) and B2 (SEQ ID NO: 7). The deleted spoIIE sequence was confirmed by DNA sequencing. The absence of endospore production in the knockout strain was visually determined after growth in spore-inducing medium and compared with the parent Brevibacillus laterosporus G2 strain (cells cultured overnight in TSB medium were collected by centrifugation and inoculated into spore-forming medium (8 g / L nutrient broth, 1 g / L KCl, 1 mM MgSO4, 1 mM Ca(NO3)2, 10 μM MnCl2, 1 μm FeSO4). Cells were grown at 33°C with agitation (200 rpm), and spore production was observed after 48 hours.

[0202] The spoIIE-deficient strain, which was proven to lack endospores, was named Brevibacillus laterosporus A8.11 and deposited with the Westerdijk Fungal Biodiversity Institute (WFDB) under the number CBS149109.

[0203] Knockout of non-essential genes in Brevibacillus laterosporus The Brevibacillus laterosporus strain contains genes associated with antibiotic resistance. In one embodiment, it is desirable to remove genes that may confer antibiotic resistance, particularly in Brevibacillus laterosporus-producing strains (strains used for large-scale / commercial production of Brevibacillus laterosporus fermentations). Removal of a series of genes associated with vancomycin resistance was achieved using a homologous recombination vector (SEQ ID NO: 8) targeting the entire operon in Brevibacillus laterosporus A8.11 (CBS14109). A DNA synthesis compartment corresponding to the genome directly upstream of the vancomycin resistance gene, directly linked to the downstream compartment, was synthesized so that the synthetic sequence would remove all intervening sequences containing the gene (SEQ ID NO: 9; Integrated DNA Technologies, Coralville, Iowa). The synthetic DNA construct was assembled and incorporated into the integration vector (Leenhouts, KJ, et al., 1991, Plasmid, 26(1), 55-66; Maguin, E., et al., 1992, J Bacteriol, 174(17), 5633-5638). The success of assembling the synthetic construct into the integration vector was determined by PCR using primer set A3 (SEQ ID NO: 10) and primer set B3 (SEQ ID NO: 11). The deleted vancomycin resistance operon sequence was confirmed by DNA sequencing using the same primers (SEQ ID NO: 10 and SEQ ID NO: 11).

[0204] Additional genes potentially associated with vancomycin resistance were removed using a homologous recombination vector (SEQ ID NO: 12) targeting a location within the Brevibacillus laterosporus A8.11 genome. A DNA synthesis compartment corresponding to the genome directly upstream of the putative vancomycin resistance gene was synthesized, directly ligated to the downstream compartment, so that the synthetic sequence removes all intercalating sequences containing the gene (SEQ ID NO: 13; Integrated DNA Technologies, Coralville, Iowa). The success of assembling the synthetic construct into the integration vector was determined by PCR using primer set C (SEQ ID NO: 14) and primer set D (SEQ ID NO: 15). The deleted vancomycin resistance operon sequence was confirmed by DNA sequencing using the same primers (SEQ ID NO: 14 and SEQ ID NO: 15).

[0205] The Brevibacillus laterosporus strain also contains a gene associated with virulence factors (cytolysin). In one embodiment, particularly in the case of Brevibacillus laterosporus-producing strains, removal of the cytolysin gene is desirable. The cytolysin gene (SEQ ID NO: 16) was removed using a homologous recombination vector targeting its location within the Brevibacillus laterosporus genome. A DNA synthetic compartment corresponding to the genome directly upstream of the cytolysin gene was synthesized, directly ligated to the downstream compartment, so that the synthetic sequence removes all intercalating sequences containing the gene (SEQ ID NO: 17; Integrated DNA Technologies, Coralville, Iowa). Synthetic DNA constructs were assembled and incorporated into the integration vector (Leenhouts, KJ, et al., 1991, Plasmid, 26(1), 55-66; Maguin, E., et al., 1992, J Bacteriol, 174(17), 5633-5638). The success of assembling the synthetic constructs into the integration vector was determined by PCR using primer set E (SEQ ID NO: 18) and primer set F (SEQ ID NO: 19). The deleted vancomycin-resistant operon sequence was confirmed by DNA sequencing using the same primers (SEQ ID NO: 18 and SEQ ID NO: 19).

[0206] Three vancomycin and citricin-deficient strains (confirmed by DNA sequencing as described above) were isolated from the final step of three consecutive knockouts. The three strains were named Brevibacillus laterosporus ALS311, Brevibacillus laterosporus ALS317, and Brevibacillus laterosporus ALS321, respectively, and deposited at the Westerdijk Fungal Biodiversity Institute (WFDB) under numbers CBS149785, CBS149786, and CBS149788, respectively.

[0207] Example 2 Fermented product of Brevibacillus laterosporus Brevibacillus laterosporus strains were grown in TSB medium (1.7% tryptone, 0.3% soytone, 0.25% glucose, 0.5% sodium chloride, 0.25% dibasic potassium phosphate) in a 250 ml baffled shaking flask and incubated at 33°C and 250 RPM for 16-18 hours. After 16-18 hours of incubation, the cells were transferred to fresh TSB medium with optional glucose (10 g / L) added in a 2 L baffled flask, or to M9 medium (0.64% Na2HPO4-7H2O, 0.15% KH2PO4, 0.025% NaCl, 0.05% NH4Cl, 10% glucose), or to M9 medium + maltodextrin (0.64% Na2HPO4-7H2O, 0.1 The cells were transferred to either M9 culture medium (5% KH2PO4, 0.025% NaCl, 0.05% NH4Cl, 10% maltodextrin) or M9 culture medium (0.64% Na2HPO4-7H2O, 0.15% KH2PO4, 0.025% NaCl, 0.05% NH4Cl, 10% maltodextrin, 5% urea) (final volume 400 mL) until the optical density reached 0.3 (absorbance at 600 nm). Using an AirOtop seal, the cells were grown at 33°C and 90 RPM for 48 hours. Optionally, the fermentation volume could be reduced, or the fermentation duration could be increased up to 4 days. To obtain a larger volume of fermentation broth, fermentation was carried out in a 500 mL bioreactor, a 2 L fermentation tank, or a 14 L fermentation tank. For larger fermentation tanks, defoaming agents such as Foamblast® 882 and DyStar International can be used.

[0208] The Brevibacillus laterosporus strain can be grown in any medium that allows for cell proliferation.

[0209] The fermented product (fermentation broth containing a mixture of culture medium and cells) was collected from the growth vessel after 48 hours of incubation.

[0210] Example 3 Brevibacillus laterosporus fermented extract An extract of the fermented product of Brevibacillus laterosporus was obtained as follows.

[0211] Cell-free supernatant of Brevibacillus laterosporus fermentation Cells were pelletized (centrifuged at 4,000-8,000 × g), and the supernatant was passed through a 0.2 μm filter to remove cells from the Brevibacillus laterosporus ferment, obtaining a substantially cell-free supernatant.

[0212] Cell pellet extract of fermented Brevibacillus laterosporus Cells were pelletized (centrifuged at 4,000-8,000 × g), the supernatant was drained, and a portion of the cell pellet was left to obtain a cell pellet extract from the ferment of Brevibacillus laterosporus. The pellet was resuspended in acidic water (1 / 10 v / v) to pH 2.5-4.0, vortexed, and pelletized again by centrifugation (4,000-8,000 × g), and the extract was passed through a 0.2 μM filter.

[0213] Starting with a cell pellet has the advantage of allowing the volume of resuspension (extract volume) to be determined to produce an effective amount of active extract, and / or further concentration to produce an effective amount of active extract. Furthermore, by resuspending the pellet in water or non-fermented broth liquid, inactive components of the fermented broth that may interfere with the active substances in the cell pellet extract are reduced or removed.

[0214] A combination of cell-free supernatant and cell pellet extract from the fermentation of Brevibacillus laterosporus. The fermented extract of Brevibacillus laterosporus can also be produced by combining the cell-free supernatant fraction described above with the cell pellet extract described above.

[0215] Whole Broth Brevibacillus Laterosporus Fermented Extract To obtain a whole broth ferment extract, the Brevibacillus laterosporus ferment extract was prepared by first adjusting the pH of the ferment (whole ferment broth prepared as described in Example 2) to pH 2.5-4.0, then pelletizing the insoluble cellular material, filtering the supernatant through a 0.2 μM filter, and obtaining a pH-adjusted cell-free supernatant. Hydrochloric acid is preferred for pH adjustment, but any acid capable of adjusting the pH of the ferment broth to 2.5 can be used. When preparing the whole broth ferment extract of Brevibacillus laterosporus ferment in this way, the active substances present in both the cell-free supernatant and the cell pellet extract are included.

[0216] Alternatively, a whole broth ferment extract of Brevibacillus laterosporus can be prepared by first adjusting the pH of the ferment (whole ferment broth) to an alkaline pH, then pelletizing the insoluble cellular material, and optionally filtering the supernatant through a 0.2 μM filter to obtain a cell-free supernatant (also called "whole broth ferment extract").

[0217] Example 4 Brevibacillus laterosporus ferment extract for suppressing the malodor of axillary osmidrosis produced by S. hominis. The ability of Brevibacillus laterosporus ferment extract to reduce and / or prevent odor generation was investigated.

[0218] B. laterosporus strain G11_1_1 was grown in a 125 ml aerated flask containing 25 ml of triptych soybean broth (TSB) in a shaking incubator (200 rpm) at 32°C for 28 hours. Cells were removed from the ferment by centrifugation at 4000 rpm for 20 minutes to obtain a cell-free supernatant (referred to as supernatant ferment extract). The supernatant was filtered and sterilized for experimental use. A second Brevibacillus laterosporus ferment extract was obtained by resuspending the cell pellet in TSB medium to the original volume of the ferment and further extracting the active substances by lowering the pH of the mixture to 0.2 using 4N HCl. Before inclusion in the odor generation assay, the pH of the cell pellet extract (referred to as cell pellet ferment extract) was further adjusted back to 4.5 with 4N NaOH.

[0219] Staphylococcus hominis (S. hominis) ATCC27844 was used as a target organism for odor generation.

[0220] For the odor generation assay, 10 ml headspace vials fitted with screw caps featuring PTFE / blue silicone septums (Supelco, Pennsylvania, USA) were used. A fresh overnight culture of the target organism, S. hominis strain ATCC27844, grown in TSB at 37°C, was diluted in TSB medium to an OD of 0.2 (600 nm). In the assay, 3.7 ml of this diluted culture was added to each vial. An equal volume of TSB medium was used as a control. The experiment was performed three times. The vials were placed in plastic holders and incubated in a shaking incubator at 37°C and 200 rpm for 24 hours. After incubation, volatile substances in the headspace were analyzed by GC-MS. Gas chromatography (GC) analysis was performed using an Agilent 7890A gas chromatograph equipped with an Agilent 7000 mass spectrometer and a Gerstel MPS Robotic Pro autosampler. Prior to use, divinylbenzene-carboxene-polydimethylsiloxane 50 / 30 μm (DVB / CAR / PDMS) SPME fibers were conditioned by inserting them into a fiber conditioning module at 280°C for 5 minutes. The SPME program consisted of shaking the sample vial at 250 rpm at 60°C for 5 minutes, then inserting the fibers into headspace at 60°C for 30 minutes, and finally transferring the fibers to a GC injector for desorption at 250°C for 2.5 minutes.

[0221] GC injection was performed in splitless mode at 250°C for 2.5 minutes. An Agilent J&W HP-FFAP capillary column (30 m × 0.25 mm, with a 0.25 μm film thickness) was used with a constant flow rate of helium carrier gas at 1 ml / min. The oven temperature was started at 40°C, held for 2 minutes, and then increased to 250°C at a rate of 15°C / min. Full scan mode (m / z 35-350) was applied to confirm the identification of all target compounds and peak identification. Peak areas were calculated using Agilent MassHunter Qualitative analysis software.

[0222] [Table 2]

[0223] As shown in Table 2, the S. hominis strain ATCC27844 was able to produce a variety of volatile odor compounds. These compounds included fatty acids and alcohol molecules. The production of these compounds was reduced or prevented by adding either a cell supernatant ferment extract or a cell pellet ferment extract of B. laterosporus. These results demonstrate the usefulness of these ferment extracts for use in suppressing axillary odor.

[0224] Example 5 Effect of Brevibacillus laterosporus fermentation extract on the proliferation of S. hominis in the presence of callus The ability of a fermented extract of Brevibacillus laterosporus to reduce and / or prevent the growth of S. hominis in the presence of callus was investigated. Callus-based skin stratum corneum models have been used to study the survival and growth of skin bacteria (van der Krieken, et al., Acta. Derm. Venereol. 96:873-879, 2016). In this model, human callus is used as a substrate and nutrient for bacterial growth. Human callus was collected from the heel (foot), mixed, frozen in liquid nitrogen, and pulverized.

[0225] B. laterosporus strain G11_1_1 was grown in a 125 ml aerated flask containing 25 ml of triptych soybean broth (TSB) in a shaking incubator (200 rpm) at 32°C for 28 hours. Cells were removed from the ferment by centrifugation at 4000 rpm for 20 minutes to obtain a cell-free supernatant (referred to as supernatant ferment extract). The supernatant (ferment) was filtered and sterilized for experimental use. A second Brevibacillus laterosporus ferment extract was obtained by resuspending the cell pellet in TSB medium to the original volume of the ferment and further extracting the active substances by lowering the pH of the mixture to 0.2 using 4N HCl. Before assay, the pH of the extract (referred to as cell pellet ferment extract) was adjusted back to 4.5 with 4N NaOH.

[0226] The starting culture of the target organism S. hominis strain ATCC27844, grown in TSB at 37°C, was diluted in TSB medium to an OD of 0.2 (600 nm).

[0227] To evaluate the effect of Brevibacillus laterosporus G11_1_1 fermentation extract on the proliferation of S. hominis, a callus assay was performed as previously described (van der Krieken, et al., 2026, Acta Derm. Venereol 96:873-879). Supernatant fermentation extract or cell pellet fermentation extract was added to agar at a final concentration of 2% in a 24-well microtiter. 0.1 ml of 2% callus suspension was added to the top of the agar. After drying, 20 ul of overnight culture of S. hominis ATCC27844 at 1.0 OD (600 nm) was added. After drying the plate, it was incubated at 37°C for 48 hours. After incubation, cells from each well were suspended in phosphate-buffered saline (PBS) and plated onto TSB plates. The number of colonies was counted, and the effectiveness of proliferation prevention by supernatant or cell extract was quantified using colony-forming units (CFU / ml).

[0228] [Table 3]

[0229] As shown in Table 3, the control without supernatant or cell extract was 4.2 × 10 6 It has a CFU count of 10, while in the presence of the supernatant fermentation extract the CFU count is 2.0 × 10 6 The levels were reduced, suggesting that the supernatant has moderate activity in preventing the proliferation of S. hominis in callus assays. On the other hand, no viable cells were observed in the presence of the cell pellet fermentation extract, indicating that the cell pellet fermentation extract has strong growth inhibitory activity.

[0230] Example 6 A fermented extract of Brevibacillus laterosporus for suppressing foot odor. The ability of a fermented extract of Brevibacillus laterosporus to reduce and / or prevent foot odor was investigated.

[0231] Isovaleric acid is a key component of foot odor (Katsutoshi Ara et al., 2006, Can J Microbiol., 52(4):357-64). The conversion of leucine to isovaleric acid is known in the industry as a method to suppress odor generation (S. Mayer et al., 2021, MicrobiologyOpen V10, issue 2). This test method can also be used to test for odor reduction. The present invention has been modified to test the overall reduction of isovaleric acid production in the presence and absence of Brevibacillus laterosporus ferment extract, as described below.

[0232] Cell-free supernatant of a Brevibacillus laterosporus ferment (e.g., Brevibacillus laterosporus ferment extract) was prepared as described in Example 3.

[0233] Samples of Brevibacillus laterosporus with and without cell-free supernatant were prepared. Each sample was prepared by adding either 1 mL of triptych soy broth (TSB) or 1 mL of cell-free supernatant, 1 mL of Staphylococcus aureus ATCC#6538 to the TSB overnight, and 13 mL of growth medium. The growth medium was selected from TSB, casamino acid-based broth (10 g / L casamino acid in sterile water, pH adjusted to 7), or eccrine sweat purchased from Pickering Laboratories. 4 mL of sample was loaded into a solid-phase microextraction (SPME) vial and removed from the original sample to obtain three identical sample vials for analysis. After placing the SPME vials in a 33°C static incubator for 48 hours, GC-MS analysis was performed using an SPME fiber. This gave the sample an opportunity to generate isovaleric acid, which is responsible for foot odor.

[0234] Gas chromatography analysis was performed using an Agilent 7890A gas chromatograph equipped with an Agilent 7000 mass spectrometer and a Gerstel MPS Robotic Pro autosampler. Prior to use, divinylbenzene-carboxene-polydimethylsiloxane 50 / 30 μm (DVB / CAR / PDMS) SPME fibers were conditioned by inserting them into a fiber conditioning module at 280°C for 5 minutes. The SPME program consisted of shaking the sample vial at 250 rpm at 60°C for 5 minutes, then inserting the fibers into headspace at 60°C for 30 minutes, and then transferring the fibers to a GC injector for desorption at 250°C for 2.5 minutes. GC injection was performed in splitless mode at 250°C for 2.5 minutes. An Agilent J&W HP-FFAP capillary column (30 m × 0.25 mm, with a 0.25 μm film thickness) was used with a constant flow rate of helium carrier gas at 1 ml / min. The oven temperature was started at 40°C, held for 2 minutes, and then increased to 250°C at a rate of 15°C / min. Full scan mode (m / z 35-350) was applied to identify all target compounds and to confirm the identification and retention time of isovaleric acid. For quantification, the mass spectrometer was operated in electron ionization mode at 70 eV, and 41.1 m / z, 60 m / z, and 87 m / z ions were monitored in Selective Ion Monitoring (SIM) mode. The retention time for isovalerate was 10.33 minutes. Peak area was calculated using Agilent MassHunter Qualitative analysis software.

[0235] TSB medium blanks, eccrine sweat blanks, and casamino acid blanks were analyzed by GC-MS under the selected ion monitoring conditions described above. No peaks appeared in any of the blanks at a retention time of 10.329 minutes, suggesting that the blanks did not contain detectable levels of isovaleric acid.

[0236] Various samples (three replicates) were analyzed by GC-MS using the selective ion monitoring described above. Isovaleric acid was detected in all samples. In general, samples without cell-free supernatant had significantly higher levels of isovaleric acid compared to samples containing cell-free supernatant (Table 4).

[0237] [Table 4]

[0238] As shown in Table 4, more isovaleric acid was detected in samples without cell-free supernatant than in samples with cell-free supernatant. This suggests that cell-free supernatant was able to reduce the amount of isovaleric acid produced in the samples. Since isovaleric acid is an important component of foot odor, using cell-free supernatant can reduce foot odor.

Claims

1. An odor-suppressing composition comprising an effective amount of Brevibacillus laterosporus ferment extract, wherein the extract prevents and / or reduces body odor.

2. The odor-suppressing composition according to claim 1, wherein the Brevibacillus laterosporus ferment extract is selected from the group consisting of a cell pellet extract obtained from a Brevibacillus laterosporus ferment, a cell-free supernatant obtained from a Brevibacillus laterosporus ferment, a whole broth ferment extract obtained from a Brevibacillus laterosporus ferment, and any one combination thereof.

3. The odor-suppressing composition according to claim 1, wherein the body surface is selected from the group consisting of the axillary region of the body, skin, feet, hair, and scalp.

4. The odor-suppressing composition according to claim 1, wherein the composition is a personal care or cosmetic composition.

5. The odor-suppressing composition according to claim 1, wherein the fermented extract of Brevibacillus laterosporus or a composition containing the fermented extract is formulated in a dry formulation or a liquid formulation.

6. The personal care composition according to claim 4, wherein the composition is a deodorizing composition.

7. The deodorizing composition according to claim 6, wherein the composition is a deodorizing stick, a deodorizing spray, a deodorizing powder, or a roll-on deodorizer.

8. A deodorizing composition for preventing or reducing body odor, comprising an effective amount of Brevibacillus laterosporus ferment extract as a deodorizing active ingredient, wherein the effective amount of extract prevents and / or reduces body odor, and the ingredient is incorporated into a deodorizing vehicle.

9. i) As a deodorizing active ingredient, an effective amount of Brevibacillus laterosporus ferment extract and ii) A liquid carrier deodorizing active substance, and optionally, iii) Air freshener and A deodorizing composition containing the following:

10. The composition according to claim 1 or claim 4, further comprising an agent selected from the group consisting of an aqueous carrier, an alcohol carrier, an antiperspirant active substance, a base component, a skin emollient, a solidifying agent, a wettable agent, an emulsifier, a solubilizer, a fragrance agent, a surfactant, a thickener, a salt, and any one combination thereof.

11. A method for preventing or reducing malodorous odors from a body surface, comprising the step of applying the composition described in claim 1 or 4 to a body surface.

12. The method according to claim 11, wherein the composition is applied to the body surface of a human or animal.

13. The method according to claim 11, wherein the composition is applied to the axillary surface, skin, feet, hair, or scalp.

14. The method according to claim 12, wherein the Brevibacillus laterosporus ferment extract is selected from the group consisting of a cell pellet extract obtained from a Brevibacillus laterosporus ferment, a cell-free supernatant obtained from a Brevibacillus laterosporus ferment, a whole broth ferment extract obtained from a Brevibacillus laterosporus ferment, and any one combination thereof.

Images